Home › Filings & Releases › November 2026
Filings & Releases — November 2026
1,174 documents from 260 companies (558 releases) · updated Nov 18, 2026
No documents match these filters.
Wednesday, November 181
- ENTAEnanta Pharmaceuticals10-KAnnual report
Tuesday, November 1734
- ZBIOZenas BioPharmaReleaseZenas BioPharma Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related Disease
- SLSSELLAS Life Sciences GroupReleaseSELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaning→ BD updateSummary on the 8-K
- SLSSELLAS Life Sciences GroupReleaseSELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering→ BD updateSummary on the 8-K
- SLSSELLAS Life Sciences Group8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateThe Binary Event Gamble I've tracked since the original deep dive just landed on heads: REGAL hit its primary OS endpoint with GPS showing a hazard ratio of 0.59, p=0.035, and a median OS of 24.0 months versus 14.7 months for best available treatment — and SELLAS immediately launched a $150M underwritten public offering to fund the BLA sprint.
- SLSSELLAS Life Sciences Group424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- PTNPalatin TechnologiesReleasePalatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
- PMNProMIS NeurosciencesReleaseProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
- PEPGPepGenSCHEDULE 13D/A13D amendment→ BD updateRA Capital answered the question I told readers to watch: they bought 8,625,000 shares at $5.00 in the November offering — $43.1M of conviction — and now hold 30.5% of PEPG while the stock trades at $3.88, 22% below their average cost.
- OVIDOvid TherapeuticsEFFECTRegistration effective
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- MPLTMapLight TherapeuticsEFFECTRegistration effective
- MESOMesoblast6-KForeign issuer report · EX-99.1
- MDNAFMedicenna TherapeuticsReleaseMedicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update→ BD updateABILITY-1 closes at 152 patients with response rates intact, but the Q2 financials reveal only $3.7M CAD in the bank, Sorbie still unconfirmed, and a stock -37% — the cash cliff has arrived in real time.
- MAIAMAIA BiotechnologyReleaseMAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer→ BD update
- MAIAMAIA Biotechnology8-KCurrent report: Reg FD disclosure · EX-99.1→ BD update
- KZIAKazia Therapeutics20-FAnnual report (foreign)
- IONSIonis PharmaceuticalsReleaseTRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)→ BD updateSummary on the release
- IONSIonis PharmaceuticalsReleaseDiranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease→ BD updateThe EU just approved TRYNGOLZA for sHTG — but only for TG ≥880 mg/dL, the narrower label I flagged in November 9's update. Meanwhile, diranersen's two-year CTAD data show a 38% CDR-SB slowing and, critically, a 30% functional endpoint effect that was zero at 18 months — the exact signal that had been missing from every prior tau program.
- INBXInhibrx BiosciencesReleaseInhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma→ BD updateSummary on the 8-K
- INBXInhibrx Biosciences8-KCurrent report: other events · EX-99.1→ BD updateThe Ewing sarcoma data that lost its regulatory path in August just came back stronger — 62.7% ORR in 51 evaluable patients, mPFS 6.0 months, no hepatotoxicity signal as n doubled, and language from the CEO suggesting a regulatory filing path is back on the table ahead of tomorrow's CTOS poster.
- GLSIGreenwich LifeSciencesReleaseGreenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026
- GANXGain TherapeuticsReleaseGain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686
- GANXGain Therapeutics8-KCurrent report: other events
- EVMNEvommune8-KCurrent report: officer / director change
- EVMNEvommune424B3Prospectus (resale / update)
- EIKNEikon TherapeuticsReleaseEikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
- CYDYCytoDynReleaseCytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs
- CYDYCytoDyn8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- CTMXCytomX TherapeuticsReleaseCytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics
- CGTXCognition TherapeuticsReleaseCognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study
- BLTEBelite Bio424B5Prospectus supplement (offering)
- ARTVArtiva Biotherapeutics8-KCurrent report: officer / director change
- ARDXArdelyxSCHEDULE 13GPassive >5% holder (13G)
- ALDXAldeyra Therapeutics8-KCurrent report: listing notice
- AKBAAkebia TherapeuticsReleaseAkebia Therapeutic’s Vafseo® (vadadustat) Granted Additional Patent
- ADAGAdageneReleaseAdagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
- ADAGAdagene6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
Monday, November 16101
- ZYMEZymeworksReleaseZymeworks Announces $200 Million Share Repurchase Authorization Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibil→ BD updateSummary on the 8-K
- ZYMEZymeworks8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateWith the stock down 14% from last week's close, Zymeworks just authorized a new $200M buyback — bigger than the entire program it just completed — signaling management believes their own paper is cheap and answering the specific question I flagged after Q3 earnings.
- ZNTLZentalis PharmaceuticalsSCHEDULE 13G/A13G amendment
- ZNTLZentalis PharmaceuticalsSCHEDULE 13G/A13G amendment
- ZBIOZenas BioPharmaSCHEDULE 13G/A13G amendment
- XNCRXencorSCHEDULE 13G/A13G amendment
- XFORX4 PharmaceuticalsSCHEDULE 13G/A13G amendment
- XFORX4 PharmaceuticalsSCHEDULE 13G/A13G amendment
- XENEXenon PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- WVEWave Life SciencesSCHEDULE 13G/A13G amendment
- VYGRVoyager TherapeuticsSCHEDULE 13G/A13G amendment
- VYGRVoyager TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- VTVTvTv TherapeuticsSCHEDULE 13D/A13D amendment→ BD updateSamsara BioCapital — a specialist healthcare VC led by Dr. Srinivas Akkaraju — filed a Schedule 13D/A disclosing a ~9.9% beneficial stake in VTVT, including a November 12 block sale of 61,287 shares at $17.60 that looks like selling but was legally a redemption trade with no economic impact on Samsara's own position; the 13D designation (not passive 13G) and the stock's 18.6% slide since the last update make this worth unpacking for subscribers.
- VSTMVerastemSCHEDULE 13G/A13G amendment
- VRDNViridian TherapeuticsSCHEDULE 13G/A13G amendment
- VRDNViridian TherapeuticsSCHEDULE 13G/A13G amendment
- VRCAVerrica PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- VORVor BiopharmaSCHEDULE 13G/A13G amendment
- VORVor BiopharmaSCHEDULE 13G/A13G amendment
- VIRVir Biotechnology8-KCurrent report: material agreement, other events · EX-99.1
- VIRVir Biotechnology424B5Prospectus supplement (offering)
- VIRVir Biotechnology424B5Prospectus supplement (offering)
- VERAVera TherapeuticsSCHEDULE 13G/A13G amendment
- VERAVera TherapeuticsSCHEDULE 13G/A13G amendment
- VERAVera TherapeuticsSCHEDULE 13G/A13G amendment
- UNCYUnicycive TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- UNCYUnicycive TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- UNCYUnicycive TherapeuticsReleaseUnicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- UNCYUnicycive Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED NOVEMBER 16, 2026→ BD updateThe Q3 10-Q lands with three items that move the UNCY thesis: the original drug-product vendor was recently inspected by the FDA (a potential timeline accelerant), CMS finalized a $12.85 per-treatment binder add to the dialysis bundle starting January 1, 2027 (restructuring the TDAPA commercial argument), and the company's own warrant model cut FDA approval odds to 57.4%–60.6% — the lowest disclosed figure to date.
- UNCYUnicycive Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- TVTXTravere TherapeuticsSCHEDULE 13G/A13G amendment
- TTRXTurn TherapeuticsReleaseTurn Therapeutics to Present at Jefferies Global Healthcare Conference in London
- TTRXTurn TherapeuticsEFFECTRegistration effective
- TTRXTurn TherapeuticsEFFECTRegistration effective
- TTRXTurn Therapeutics424B5Prospectus supplement (offering)
- TTRXTurn Therapeutics424B3Prospectus (resale / update)
- TSHATaysha Gene TherapiesSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TLSATiziana Life SciencesSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- TENXTenax TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- TARAProtara TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateJanus Henderson, the anchor institutional holder I've tracked since the original deep dive at ~10–11%, has fully exited TARA as of September 30 — filing a 0-share 13G/A today while the stock sits at $2.38 and near its cash floor.
- STROSutro BiopharmaSCHEDULE 13G/A13G amendment
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- SPRBSpruce BiosciencesSCHEDULE 13G/A13G amendment
- SMMTSummit Therapeutics8-KCurrent report: other events · EX-99.1→ BD updateThe FDA said no: a CRL landed Saturday on the HARMONi BLA, citing the absence of a statistically significant OS benefit — exactly the regulatory trap I flagged in the original deep dive. The coin landed tails, but the molecule isn't dead and the war chest is intact.
- SLDBSolid BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- SGMTSagimet BiosciencesSCHEDULE 13G/A13G amendment
- SGMTSagimet BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- SEPNSepternaSCHEDULE 13G/A13G amendment
- SCYXScynexisSCHEDULE 13G/A13G amendment
- SCYXScynexisSCHEDULE 13G/A13G amendment
- SABSSAB BiotherapeuticsSCHEDULE 13G/A13G amendment
- SABSSAB BiotherapeuticsSCHEDULE 13G/A13G amendment
- SABSSAB BiotherapeuticsSCHEDULE 13G/A13G amendment
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
- RVMDRevolution MedicinesSCHEDULE 13G/A13G amendment
- RVMDRevolution MedicinesSCHEDULE 13G/A13G amendment
- RVMDRevolution MedicinesReleaseEuropean Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- RNTXRein TherapeuticsReleaseRein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Resu→ BD updateSummary on the 8-K
- RNTXRein Therapeutics8-KCurrent report: other events · EX-99.1→ BD updateThe Q4 2026 RENEW interim I called a "coin flip dressed as a signal" just landed — blinded, pooled, n=24, no treatment-arm comparison possible — and the stock dropped 27.5% in today's session on data that cannot, by design, tell us whether LTI-03 works.
- RNTXRein Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- RLMDRelmada TherapeuticsSCHEDULE 13G/A13G amendment
- RLMDRelmada TherapeuticsReleaseRelmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officervia aggregator
- RLMDRelmada Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE ISSUED ON NOVEMBER 16, 2026
- RLAYRelay TherapeuticsSCHEDULE 13G/A13G amendment
- RLAYRelay TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- REPLReplimune GroupSCHEDULE 13G/A13G amendment
- RAPPRapport TherapeuticsSCHEDULE 13G/A13G amendment
- QUITAchieve Life SciencesSCHEDULE 13G/A13G amendment
- QUITAchieve Life SciencesSCHEDULE 13G/A13G amendment
- QUITAchieve Life SciencesSCHEDULE 13G/A13G amendment
- QUITAchieve Life SciencesSCHEDULE 13G/A13G amendment
- QTTBQ32 BioSCHEDULE 13G/A13G amendment
- QTTBQ32 BioSCHEDULE 13G/A13G amendment
- QTTBQ32 BioSCHEDULE 13G/A13G amendment
- QTTBQ32 BioSCHEDULE 13GPassive >5% holder (13G)
- QNRXQuoin PharmaceuticalsSCHEDULE 13G/A13G amendment
- QNRXQuoin PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- PTNPalatin TechnologiesSCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 10-Q
- PTNPalatin TechnologiesReleasePalatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026→ BD updateSummary on the 10-Q
- PTNPalatin Technologies10-QQuarterly report→ BD updatePalatin finally named its development candidate — PL2001, a lipidated MC4R-selective peptide with >168-hour dog half-life and >100–200x selectivity over MC1R — but the same filing revealed cash has cratered to $3.74M, burning $3.75M in a single quarter. The science answered one question; the balance sheet raised a bigger one.
- PRLDPrelude TherapeuticsReleasePrelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- PRLDPrelude Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updatePrelude confirmed first patients dosed with PRT13722 in Q4 2026 and signed Eli Lilly to supply abemaciclib and imlunestrant for the Phase 1 combination cohorts — directly addressing the combinability hypothesis that was the entire bull case in the prior writeup.
- PRLDPrelude Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- PMVPPMV PharmaceuticalsSCHEDULE 13G/A13G amendment
- PMNProMIS NeurosciencesSCHEDULE 13G/A13G amendment
- PHIOPhio PharmaceuticalsSCHEDULE 13G/A13G amendment
- PCVXVaxcyteSCHEDULE 13GPassive >5% holder (13G)
- PALIPalisade BioSCHEDULE 13G/A13G amendment
- PALIPalisade BioSCHEDULE 13G/A13G amendment
- OVIDOvid TherapeuticsSCHEDULE 13G/A13G amendment
- OVIDOvid TherapeuticsSCHEDULE 13G/A13G amendment
- OTLKOutlook TherapeuticsSCHEDULE 13G/A13G amendment
- ORKAOruka TherapeuticsSCHEDULE 13G/A13G amendment
- ORKAOruka TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ORICOric PharmaceuticalsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- ORICOric PharmaceuticalsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- ORICOric PharmaceuticalsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- ORICOric PharmaceuticalsReleaseORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates→ BD updateSummary on the 8-K
- ORICOric Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateORIC's Q3 report delivers the promised rinzimetostat durability update — rPFS holding in mevrometostat's range at 8 months — but the institutional register is quietly fraying: Viking Global trimmed from 7.8% to 5.7%, EcoR1 collapsed from 6.9% to 2.9%, and the CEO and CMO both adopted new 10b5-1 selling plans for December. The balance sheet is real ($345M) but the burn is accelerating faster than the prior-year pace.
- ORICOric Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- OMEROmerosReleaseOmeros Corporation Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- OMEROmeros8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateYARTEMLEA posted $35.9M net / $41.8M gross in Q3 — a third consecutive quarter of growth, 109 ordering accounts, and $4.5M operating income — with the CEO confirming Q4 momentum is continuing and a new 2027 outpatient reimbursement tailwind on the horizon.
- OMEROmeros10-QQuarterly report→ BD updateSummary on the 8-K
- OLMAOlema PharmaceuticalsSCHEDULE 13G/A13G amendment
- OKUROnKure TherapeuticsSCHEDULE 13G/A13G amendment
- OCSOculis HoldingReleaseOculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
- NRXPNRX Pharmaceuticals10-QQuarterly report→ BD updateThe Q3 10-Q reveals NRX burned $19.9M in nine months, holds $19.8M in cash at September 30, and confirms the DARPA contract is signed and already billing — but the runway math is tighter than the post-June-raise bridge implied, and a $712K aircraft on the balance sheet raises new questions.
- NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
- NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
- NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
- NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
- NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
- NGNENeurogeneSCHEDULE 13G/A13G amendment
- NGNENeurogeneSCHEDULE 13G/A13G amendment
- NGNENeurogeneSCHEDULE 13G/A13G amendment
- NGNENeurogeneSCHEDULE 13G/A13G amendment
- NGENNervGen PharmaReleaseNervGen Reports Third Quarter 2026 Financial Results and Provides Business Updatesvia aggregator→ BD updateSummary on the 6-K
- NGENNervGen Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateNervGen's Q3 2026 financials confirm C$80.1M cash, RESTORE enrollment underway, and the first post-restatement quarter with the new controls in place — but the burn is accelerating and the base shelf expires December 25.
- NAMSNewAmsterdam PharmaSCHEDULE 13G/A13G amendment
- NAMSNewAmsterdam PharmaSCHEDULE 13GPassive >5% holder (13G)
- MRKRMarker Therapeutics10-QQuarterly report→ BD updateQ3 numbers drop after the close: $9.4M cash, zero financing, APOLLO still silent, and the stock has surrendered every dollar of October's grant-driven pop — the dilution clock is running faster than the data clock.
- MPLTMapLight TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- MPLTMapLight TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- MPLTMapLight TherapeuticsS-3Shelf registration→ BD updateSummary on the 8-K
- MPLTMapLight TherapeuticsReleaseMapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- MPLTMapLight TherapeuticsPOS AMPost-effective amendment→ BD updateSummary on the 8-K
- MPLTMapLight Therapeutics8-KCurrent report: material agreement→ BD updateMapLight quietly opened a $100M ATM facility with Leerink today — and T. Rowe Price cut its stake by ~66%, from 6.17% to 1.7%, while the market wasn't watching. Two new overhang sources hit simultaneously, right as ZEPHYR-2 gets a formal 2028 timeline.
- MPLTMapLight Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateSummary on the 8-K
- MPLTMapLight Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- MGTXMeiraGTxSCHEDULE 13G/A13G amendment
- MGTXMeiraGTxReleaseMeiraGTx Announces Oral Presentation at ObesityWeek 2026
- MESOMesoblast6-KForeign issuer report · EX-99.1
- MDNAFMedicenna TherapeuticsReleaseMedicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Con→ BD updateThe second of Medicenna's Q4 data events landed today at SNO 2026: bizaxofusp more than doubled median overall survival versus a matched external control in the Phase 3-relevant IDH-WT glioblastoma population — the strongest partnership-predicate package the company has ever assembled, arriving while the stock is down 17.5% on the week and the Sorbie clock is still ticking.
- MBXMBX BiosciencesSCHEDULE 13G/A13G amendment
- MBRXMoleculin BiotechSCHEDULE 13G/A13G amendment
- MBRXMoleculin BiotechReleaseMoleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
- MBRXMoleculin Biotech8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- MAZEMaze TherapeuticsSCHEDULE 13G/A13G amendment
- LXEOLexeo TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- LXEOLexeo TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- LXEOLexeo TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- LXEOLexeo TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- LXEOLexeo TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- LXEOLexeo TherapeuticsReleaseLexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-Kcompany site may be offline after the acquisition; linked to the SEC copy · original
- LXEOLexeo Therapeutics8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1→ BD updateToday's HEROIC-PKP2 interim data delivered what January's readout couldn't: an 80% mean NSVT reduction in high-dose patients that deepens over time, 100% below the clinically meaningful arrhythmia threshold at latest assessment, and FDA confirmation that NSVT can serve as the primary surrogate endpoint for accelerated approval — giving LX2020 a pivotal path and a 2H 2027 start date.
- LXEOLexeo Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- LRMRLarimar TherapeuticsSCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- LRMRLarimar TherapeuticsS-8Employee plan registration→ BD updateSummary on the 8-K
- LRMRLarimar TherapeuticsReleaseLarimar Therapeutics Reports Third Quarter 2026 Financial and Business Update→ BD updateSummary on the 8-K
- LRMRLarimar Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateLarimar's Q3 earnings confirm the BLA is in and the milestone calendar is set — but the runway just shrank to late Q2 2027, the fill-and-finish Form 483 language hardened, and RTW Investments just disclosed a fresh 5.6% stake. Here's where things stand heading into the FDA acceptance window.
- LRMRLarimar Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- LGVNLongeveronSCHEDULE 13G/A13G amendment
- LBRXLB PharmaceuticalsSCHEDULE 13G/A13G amendment
- LBRXLB PharmaceuticalsSCHEDULE 13G/A13G amendment
- LBRXLB PharmaceuticalsSCHEDULE 13G/A13G amendment
- KZIAKazia TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- KYTXKyverna TherapeuticsSCHEDULE 13G/A13G amendment
- KURAKura OncologySCHEDULE 13G/A13G amendment
- KTTAPasithea TherapeuticsSCHEDULE 13G/A13G amendment
- KTTAPasithea TherapeuticsSCHEDULE 13G/A13G amendment
- KTTAPasithea TherapeuticsSCHEDULE 13G/A13G amendment
- KTTAPasithea Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED NOVEMBER 13, 2026
- KROSKeros TherapeuticsReleaseKeros Therapeutics Announces Additional $5 Million Share Repurchase Authorization
- KROSKeros Therapeutics8-KCurrent report: other events · EX-99.1
- KPRXKiora PharmaceuticalsSCHEDULE 13G/A13G amendment
- KODKodiak SciencesSCHEDULE 13G/A13G amendment
- KODKodiak SciencesSCHEDULE 13G/A13G amendment
- JBIOJade BiosciencesSCHEDULE 13G/A13G amendment
- JBIOJade BiosciencesSCHEDULE 13G/A13G amendment
- JBIOJade BiosciencesSCHEDULE 13G/A13G amendment
- JBIOJade BiosciencesSCHEDULE 13G/A13G amendment
- IVVDInvivydSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- IVVDInvivydSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- IVVDInvivydReleaseInvivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights→ BD updateSummary on the 8-K
- IVVDInvivyd8-KCurrent report: results of operations · EX-99.1→ BD updateDECLARATION data slips again to "imminent" while cash burns at ~$13M/month, Perceptive exits below 5%, RA Capital's pre-funded warrants convert to 21M shares in November, and VYD2311 gets an INN — the thesis hasn't changed, but the runway just got measurably shorter.
- IVVDInvivyd10-QQuarterly report→ BD updateSummary on the 8-K
- IRDOpus GeneticsSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsSCHEDULE 13G/A13G amendment
- IRDOpus GeneticsSCHEDULE 13GPassive >5% holder (13G)
- IRDOpus GeneticsSCHEDULE 13GPassive >5% holder (13G)
- INMBInmune BioSCHEDULE 13G/A13G amendment
- INABIN8bioReleaseIN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy→ BD updateThe SNO oral session delivered what the November 5 update said to watch for: a final mOS of 20.9 months (+59% vs. SOC's 13.2 months) and 50% two-year survival vs. 10% in controls — the total repeat-dose dataset, not just a subgroup, with zero CRS/ICANS/treatment-related SAEs across up to six doses.
- IMUXImmunicSCHEDULE 13G/A13G amendment
- IMUXImmunicSCHEDULE 13G/A13G amendment
- IMTXImmaticsSCHEDULE 13G/A13G amendment
- IMTXImmaticsSCHEDULE 13G/A13G amendment
- IMTXImmaticsSCHEDULE 13GPassive >5% holder (13G)
- IMNMImmunomeSCHEDULE 13GPassive >5% holder (13G)
- IMCRImmunocoreSCHEDULE 13G/A13G amendment
- IDYAIDEAYA BiosciencesReleaseIDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TO→ BD updateFDA has now blessed registrational paths for IDE849 in *both* SCLC and NEC — adding ~15,000 annual U.S. NEC patients to the addressable pool — but three simultaneous Phase 3s against a mid-2029 cash runway forces a harder look at capital allocation before the Western efficacy data even lands.
- HROWHarrow8-KCurrent report: Reg FD disclosure · EX-99.1 EX-99.1 CORPORATE PRESENTATION DATED NOVEMBER 2026
- HRMYHarmony BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- HELPHelus PharmaSCHEDULE 13G/A13G amendment→ BD updateSummary on the 6-K
- HELPHelus PharmaSCHEDULE 13G/A13G amendment→ BD updateSummary on the 6-K
- HELPHelus PharmaReleaseHelus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder→ BD updateSummary on the 6-K
- HELPHelus PharmaReleaseHelus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights→ BD updateSummary on the 6-K
- HELPHelus Pharma6-KForeign issuer report · EX-99.1→ BD updateSummary on the 6-K
- HELPHelus Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateSummary on the 6-K
- HELPHelus Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateThe APPROACH Phase 3 coin flip has landed — HLP003 beat placebo on both primary and key secondary endpoints with p<0.0001, but the Phase 3 effect size (d=0.653) came in well below the Phase 2's d=2.15, and HELP is down -13.5% on what most would read as a positive readout.
- GRCEGrace TherapeuticsSCHEDULE 13G/A13G amendment
- GPCRStructure TherapeuticsSCHEDULE 13G/A13G amendment
- GPCRStructure TherapeuticsSCHEDULE 13G/A13G amendment
- GOSSGossamer BioSCHEDULE 13G/A13G amendment
- GOSSGossamer BioS-3Shelf registration
- GNLXGeneluxReleaseGenelux Corporation Reports Third Quarter Financial Results and Provides Business Updates→ BD updateSummary on the 10-Q
- GNLXGenelux10-QQuarterly report→ BD updateThe Q3 10-Q reveals a ~$5.1M post-quarter ATM dump at ~$2/share that roughly doubled the ATM's total haul from inception, the Chief Scientific Officer adopted a sell plan for up to 98,000 shares, and accrued R&D liabilities surged to $8.1M — the runway-meets-binary squeeze is now tighter than ever, and the smart-money signals are pointing the wrong way with the Phase 3 readout still unscheduled within "2H 2026."
- GLUEMonte Rosa TherapeuticsSCHEDULE 13G/A13G amendment
- GLUEMonte Rosa TherapeuticsSCHEDULE 13G/A13G amendment
- GLUEMonte Rosa TherapeuticsSCHEDULE 13G/A13G amendment
- GLUEMonte Rosa TherapeuticsSCHEDULE 13G/A13G amendment
- GLSIGreenwich LifeSciences10-QQuarterly report→ BD updateThe Q3 10-Q just blew up the burn-moderation narrative: R&D expense re-accelerated 67% YoY to $5.45M in a single quarter, cash fell to $5.90M against $6.90M in accounts payable, and the company has flipped into a stockholders' deficit — the financial floor the August update called "firmer" just cracked.
- GHRSGH ResearchSCHEDULE 13G/A13G amendment
- GHRSGH ResearchSCHEDULE 13G/A13G amendment
- FDMT4D Molecular TherapeuticsSCHEDULE 13G/A13G amendment
- FDMT4D Molecular TherapeuticsSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- EYPTEyePointSCHEDULE 13G/A13G amendment
- EYPTEyePointSCHEDULE 13G/A13G amendment
- EWTXEdgewise TherapeuticsSCHEDULE 13G/A13G amendment
- EVMNEvommuneSCHEDULE 13G/A13G amendment
- EVMNEvommuneSCHEDULE 13G/A13G amendment
- ETONEton PharmaceuticalsSCHEDULE 13G/A13G amendment
- ERASErascaSCHEDULE 13G/A13G amendment
- ERASErascaSCHEDULE 13G/A13G amendment
- ERASErascaReleaseErasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
- ENTAEnanta PharmaceuticalsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- ENTAEnanta PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026→ BD updateSummary on the 8-K
- ENTAEnanta Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateEnanta's fiscal Q4 print landed after the close today with a cluster of negatives: EDP-978 Phase 1 topline slipped to 1Q 2027, the STAT6 "oral Dupixent" IND pushed to 2Q 2027 on a drug manufacturing delay, the workforce was cut by one-third, cash fell to $194.5M as RESOLVE and LOTUS ramp, and Farallon — the smart-money anchor I cited in the deep dive — quietly trimmed from ~9-10% to 3.3%.
- ELVNEnliven TherapeuticsSCHEDULE 13G/A13G amendment
- ELOXEloxx PharmaceuticalsReleaseEloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
- ELOXEloxx Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
- ELOXEloxx Pharmaceuticals424B3Prospectus (resale / update)
- ELOXEloxx Pharmaceuticals10-QQuarterly report
- ELDNEledon PharmaceuticalsSCHEDULE 13G/A13G amendment
- DYNDyne TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- DTILPrecision BiosciencesSCHEDULE 13G/A13G amendment
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 INVESTOR PRESENTATION DATED NOVEMBER 16, 2026→ BD updateREGAIN's SNO 2026 interim shows 100% ORR and 8/8 patients alive in recurrent GBM — but the -10.5% Monday selloff reflects the radiation necrosis signal in 4 of 6 patients and two open imaging questions the market isn't yet willing to dismiss.
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED NOVEMBER 15, 2026.→ BD updateSummary on the 6-K
- DFTXDefinium TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CUECue BiopharmaSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- CUECue BiopharmaSCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- CUECue BiopharmaSCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- CUECue BiopharmaReleaseCue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights→ BD updateSummary on the 8-K
- CUECue Biopharma8-KCurrent report: results of operations · EX-99.1→ BD updateNew high-IgE subgroup data from the Phase 2 CSU study expand the food allergy commercial thesis, CUE-401 enters the clinic, Balyasny crosses 5% while the stock has cratered 50% from the data-day close — time to decode what's driving the drawdown and where the thesis stands.
- CUECue Biopharma10-QQuarterly report→ BD updateSummary on the 8-K
- CTNMContineum TherapeuticsSCHEDULE 13G/A13G amendment
- CTNMContineum TherapeuticsSCHEDULE 13G/A13G amendment
- CRVOCervoMedReleaseCervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia→ BD updateSummary on the 8-K
- CRVOCervoMed8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateThe CTAD nfvPPA 24-week data arrived after the close: patients in the upper tertile of drug exposure showed a median 4.5 pg/mL NfL reduction over 24 weeks while lower-exposure patients tracked natural history (+4.35 pg/mL), neatly replicating the ~4 ng/mL trough threshold that explains the DLB Bad Batch story — adding real fuel to the partner pitch without changing the binary structure.
- CRNXCrinetics PharmaceuticalsSCHEDULE 13G/A13G amendment
- CRNXCrinetics PharmaceuticalsSCHEDULE 13G/A13G amendment
- CNTBConnect BiopharmaSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- CNTBConnect BiopharmaReleaseConnect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- CNTBConnect Biopharma8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q landed after today's close with a formal going-concern disclosure, a Nasdaq bid-price deficiency notice received November 12, and a footnote revealing Connect already sold 1.5M shares via ATM in October for just $1.8M in net proceeds (~$1.20/share) — the dilution trap I warned about has sprung.
- CNTBConnect Biopharma10-QQuarterly report→ BD updateSummary on the 8-K
- CLRBCellectar BiosciencesSCHEDULE 13G/A13G amendment
- CLDXCelldex TherapeuticsSCHEDULE 13G/A13G amendment
- CGONCG OncologyReleasePIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)→ BD updateSummary on the 8-K
- CGONCG Oncology8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updatePIVOT-006 just delivered a hazard ratio of 0.32 (p<0.0001) in a randomized Phase 3 against surveillance — a 68% cut in recurrence risk with zero Grade 3+ TRAEs. The salvage-therapy story just became the backbone-therapy story.
- CCCCC4 TherapeuticsSCHEDULE 13G/A13G amendment
- CCCCC4 TherapeuticsSCHEDULE 13G/A13G amendment
- CBIOCrescent BiopharmaSCHEDULE 13G/A13G amendment
- CBIOCrescent BiopharmaSCHEDULE 13G/A13G amendment
- CBIOCrescent BiopharmaSCHEDULE 13G/A13G amendment
- CBIOCrescent BiopharmaSCHEDULE 13G/A13G amendment
- CATXPerspective TherapeuticsSCHEDULE 13G/A13G amendment
- CAPRCapricor TherapeuticsSCHEDULE 13G/A13G amendment→ BD update
- CAMPCamp4 TherapeuticsSCHEDULE 13G/A13G amendment
- CADLCandel TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateRTW Investments — Candel's royalty financier and former 8.8% anchor holder — quietly cut its equity stake nearly in half to 4.2% as of September 30. When the entity that gets paid $100M only on approval is selling stock, the read-through is not friendly.
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- BIOABioAge LabsSCHEDULE 13G/A13G amendment
- BCYCBicycle TherapeuticsSCHEDULE 13G/A13G amendment
- BCRXBiocryst PharmaceuticalsSCHEDULE 13G/A13G amendment
- AUTLAutolus TherapeuticsSCHEDULE 13G/A13G amendment
- AUTLAutolus TherapeuticsSCHEDULE 13G/A13G amendment
- ARVNArvinasSCHEDULE 13G/A13G amendment
- APVOAptevo TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- APVOAptevo TherapeuticsReleaseAptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results→ BD updateSummary on the 8-K
- APVOAptevo Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q lands with $8.3M cash, 19.1M warrants outstanding against 3.5M shares, and a Nasdaq market-value reading of $2.9M — but 10 of 47 frontline AML patients have now bridged to curative transplant, and a priming-dose tweak has materially cut infusion reactions.
- APVOAptevo Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- ANTXAN2 TherapeuticsSCHEDULE 13G/A13G amendment
- ANNXAnnexonSCHEDULE 13G/A13G amendment
- ANABAnaptysBioSCHEDULE 13G/A13G amendment
- AMLXAmylyx PharmaceuticalsSCHEDULE 13G/A13G amendment→ BD updateSummary on the release of Nov 14, 2026
- AMLXAmylyx PharmaceuticalsSCHEDULE 13G/A13G amendment→ BD updateSummary on the release of Nov 14, 2026
- ALTAltimmuneSCHEDULE 13G/A13G amendment
- ALLOAllogene TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- AKTSAktis OncologySCHEDULE 13GPassive >5% holder (13G)
- AKBAAkebia TherapeuticsReleaseAkebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million→ BD update
- AKBAAkebia Therapeutics8-KCurrent report: material agreement, agreement terminated, debt / obligation · EX-99.1→ BD update
- AGMBAgomab TherapeuticsSCHEDULE 13G/A13G amendment
- AGIOAgios PharmaceuticalsSCHEDULE 13G/A13G amendment
- AGIOAgios PharmaceuticalsSCHEDULE 13G/A13G amendment
- ADMAAdma BiologicsSCHEDULE 13GPassive >5% holder (13G)
- ACRVAcrivon TherapeuticsS-3Shelf registration→ BD updateSummary on the 8-K
- ACRVAcrivon TherapeuticsReleaseAcrivon Reports Third Quarter 2026 Financial Results and Business Highlights→ BD updateSummary on the 8-K
- ACRVAcrivon Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateAcrivon's Q3 print dropped a going-concern flag and confirmed $77.8M cash — with the make-or-break ACR-368 serous interim now explicitly expected in Q4 2026, the dilution gap I've been warning about is arriving on schedule, and the S-3 filed after hours today likely signals what comes next.
- ACRVAcrivon Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- ACRSAclaris TherapeuticsSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- ACRSAclaris TherapeuticsReleaseAclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)→ BD updateSummary on the 8-K
- ACRSAclaris TherapeuticsReleaseAclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)→ BD updateSummary on the 8-K
- ACRSAclaris Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateBosakitug's 109-patient randomized Phase 2 ADMIRATION trial failed every endpoint — primary and secondary — the moment I'd called the "prove-it moment" for the TSLP monoclonal franchise. The read-through to ATI-052's TSLP arm is the question the thesis now has to answer.
- ABVXAbivaxSCHEDULE 13G/A13G amendment
- AARDAardvark TherapeuticsSCHEDULE 13G/A13G amendment
Sunday, November 156
- VKTXViking TherapeuticsReleaseViking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
- SMMTSummit TherapeuticsReleaseSummit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application→ BD updateSummary on the 8-K of Nov 16, 2026
- MESOMesoblastReleaseMesoblast Showcased at ASX Premier Investor Day Eventvia aggregator
- LXEOLexeo TherapeuticsReleaseLexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026→ BD updateSummary on the 8-K of Nov 16, 2026company site may be offline after the acquisition
- IDYAIDEAYA BiosciencesReleaseIDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors→ BD updateSummary on the release of Nov 16, 2026
- HELPHelus PharmaReleaseHelus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026→ BD updateSummary on the 6-K of Nov 16, 2026
Saturday, November 141
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting→ BD updateThe full LUCIDITY dataset landed at ObesityWeek and it's even cleaner than the topline suggested: avexitide cut hypoglycemic events from 1.24 to 0.55 per week versus placebo, all four secondary endpoints hit with p-values down to 0.0000032 — and the stock is somehow still trading 22% below the August offering price.
Friday, November 1353
- XNCRXencorSCHEDULE 13GPassive >5% holder (13G)
- XFORX4 PharmaceuticalsSCHEDULE 13G/A13G amendment
- WVEWave Life SciencesReleaseWave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
- VRCAVerrica PharmaceuticalsSCHEDULE 13G/A13G amendment
- VRCAVerrica Pharmaceuticals10-QQuarterly report
- VNDAVanda PharmaceuticalsSCHEDULE 13G/A13G amendment
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- SRPTSarepta TherapeuticsSCHEDULE 13G/A13G amendment
- SRPTSarepta Therapeutics13F-HR13F-HR
- SGMTSagimet BiosciencesSCHEDULE 13GPassive >5% holder (13G)
- RXRXRecursion PharmaceuticalsSCHEDULE 13G/A13G amendment
- RVPHReviva PharmaceuticalsReleaseReviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- RVPHReviva Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- RVPHReviva Pharmaceuticals10-QQuarterly report
- RAREUltragenyx PharmaceuticalSCHEDULE 13G/A13G amendment
- PYPDPolyPidSCHEDULE 13G/A13G amendment
- PTNPalatin TechnologiesReleasePalatin to Report First Quarter Fiscal Year 2027 Results
- PRMEPrime MedicineSCHEDULE 13GPassive >5% holder (13G)
- PRMEPrime MedicineSCHEDULE 13D/A13D amendment
- PCSAProcessa Pharmaceuticals10-QQuarterly report→ BD updateThe Q3 10-Q confirms $180M in the bank and VT-7208 on track, but buries two things worth reading: the CHZ crypto position is quietly being wound down at a loss, and a hard April 2027 deadline now hangs over the preferred-stock conversion vote that the entire thesis depends on.
- ONCYOncolytics BiotechReleaseOncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC→ BD updateSummary on the 10-Q
- ONCYOncolytics Biotech10-QQuarterly report→ BD updateOncolytics just named its first actual drug-supply partner for the anal cancer program — Coherus's toripalimab — while the Q3 10-Q reveals cash has fallen to $2.43M, the stockholders' deficit has widened to -$7.5M, and post-quarter ATM selling averaged just $0.47/share, all with the Nasdaq January 15 deadline now confirmed and the reverse split clock ticking louder.
- NTLAIntellia Therapeutics8-K/ACurrent report (amended): Reg FD disclosure · EX-99.1
- NKTRNektar Therapeutics8-KCurrent report: Reg FD disclosure→ BD updateThe Q3 10-Q quietly buries a material change: ZENITH AD-2 has been redesigned from a monotherapy trial into a combination study with topical corticosteroids — a protocol shift that narrows what that pivotal will prove on its own, while the 8-K finally puts in writing that cash clears the summer 2028 ZENITH readout.
- NKTRNektar Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data→ BD updateSummary on the 8-K
- MISTMilestone Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateMilestone cut 20% of its workforce, lost its CFO and CMO in one announcement, and quietly revealed its own CARDAMYST revenue model is weaker than advertised — but it also bought itself a runway to late 2028, which changes the survival calculus entirely.
- MISTMilestone Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- MBRXMoleculin Biotech10-QQuarterly report→ BD updateThe Nasdaq Hearings Panel granted MBRX a conditional listing exception through March 15, 2027 — one of the two conditions I set for revisiting this name — but the 10-Q reveals the Series I warrant floor sits at $4.20 (post-split), ATM sales have already pushed the strike to $8.22, and $7.0M more is needed to reach Q2 2027, all with the Q1 2027 binary still unpriced.
- LXEOLexeo TherapeuticsSCHEDULE 13G/A13G amendment
- LGVNLongeveronSCHEDULE 13GPassive >5% holder (13G)
- KURAKura OncologyReleaseKura Oncology to Participate in Two Investor Conferences in November
- KTTAPasithea TherapeuticsReleasePasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 Eur→ BD updateSummary on the 10-Q
- KTTAPasithea Therapeutics10-QQuarterly report→ BD updateThe macrocycle just delivered its first real NF1 efficacy readout: 100% of evaluable cNF patients shrank, with median 41% tumor reduction and responses deepening to 71% at 15 months — no approved systemic competitor, no safety showstoppers, and a Phase 2 already IND-cleared to capitalize on it.
- KAPAKairos Pharma10-QQuarterly report→ BD updateThe 1-for-7 reverse split I told readers to treat as a re-underwriting trigger went effective September 1. The Q3 10-Q — filed after today's close — also reveals a Lonza restructuring that cuts the manufacturing obligation roughly in half, an accelerating burn rate, three Helena ELOC amendments in October, and a new NYSE American $0.25 minimum price rule that KAPA clears by only $0.20 at today's close.
- JBIOJade BiosciencesReleaseJade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- JBIOJade Biosciences8-KCurrent report: results of operations · EX-99.1→ BD updateJade's Q3 2026 numbers confirm the fortress balance sheet ($475.7M, runway into Q4 2028), validate EVERGREEN's Q4 start, add JADE301 to the Q4 clinical queue — but the ATM printed $44.5M more in the quarter, and the December 31 Parade warrant grant is crystallizing at the current price.
- JBIOJade Biosciences10-QQuarterly report→ BD updateSummary on the 8-K
- JANXJanux TherapeuticsSCHEDULE 13G/A13G amendment
- INBXInhibrx BiosciencesSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- INBXInhibrx BiosciencesS-3ASRAutomatic shelf registration→ BD updateSummary on the 8-K
- INBXInhibrx BiosciencesReleaseInhibrx Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- INBXInhibrx Biosciences8-KCurrent report: results of operations · EX-99.1→ BD updateInhibrx launched a $150M ATM equity facility after the close — the dilution I called inevitable has arrived, at $83 versus the $124 pre-data price. But buried in tonight's 10-Q is a more urgent risk: FDA Form 483 manufacturing observations on ozekibart's drug substance and drug product CMOs, a live threat to the April 14, 2027 PDUFA.
- INBXInhibrx Biosciences10-QQuarterly report→ BD updateSummary on the 8-K
- IMUXImmunicSCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- IMUXImmunicReleaseImmunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- IMUXImmunic8-KCurrent report: results of operations · EX-99.1→ BD updateWith ENSURE top-line data now pinned to December 2026, IMUX has re-priced to $7.52 — below the $8.73 smart-money PIPE mark — while Q3 cash came in at $132M and the 50% corporate-transaction probability holds. Six weeks to the binary.
- IMUXImmunic10-QQuarterly report→ BD updateSummary on the 8-K
- IMTXImmaticsSCHEDULE 13G/A13G amendment
- HURATuHURA BiosciencesReleaseTuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update→ BD updateSummary on the 8-K
- HURATuHURA Biosciences8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q lands with no Phase 3 enrollment count, $4.95M in new Parkview draws since quarter-end that accelerate the facility burn rate, and a runway statement that quietly dropped "end of" before "2028" — the bear case tightens on every axis I flagged.
- HURATuHURA Biosciences10-QQuarterly report→ BD updateSummary on the 8-K
- HELPHelus Pharma6-KForeign issuer report · EX-99.1→ BD updateHelus Pharma's Q2 FY2027 earnings confirm the APPROACH Phase 3 data is functionally imminent — only ~$2.9M in estimated remaining spend — while the ATM executed at a surprising $13.30/share average, Millennium has quietly trimmed to 1.4%, and the stock has bled -15.7% since the October founders-exit update.
- GUTSFractyl HealthSCHEDULE 13G/A13G amendment
- GRCEGrace TherapeuticsSCHEDULE 13G/A13G amendment
- GLSIGreenwich LifeSciencesReleaseGreenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TVvia aggregator
- GHRSGH ResearchReleaseGH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer Nov 13, 2026 Dr. Popova will lead the clinical development of GH001 as the company advances toward pivotal programs→ BD updateSummary on the 6-K
- GHRSGH ResearchReleaseGH Research Reports Third Quarter 2026 Financial Results and Provides Business Update Nov 13, 2026 Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support goi→ BD updateSummary on the 6-K
- GHRSGH Research6-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateGH Research's new ADS device just collapsed the pivotal-visit protocol from three doses to one — 88% peak experience rate in a single inhale — while the FDA signaled it likes the pivotal design and a former Spravato trial lead joins as CDO.
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- FBIOFortress BiotechReleaseFortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights→ BD updateSummary on the 8-K
- FBIOFortress Biotech8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings landed this morning: Emrosi hit ~40,000 scripts and $9.0M of Q3 revenue, the balance sheet is debt-free at the parent — and the preferred arrears just hit $18.1M for the seventh consecutive quarter of management inaction.
- FBIOFortress Biotech10-QQuarterly report→ BD updateSummary on the 8-K
- ENTXEntera BioSCHEDULE 13GPassive >5% holder (13G)
- ELTXElicio Therapeutics8-KCurrent report: shareholder vote
- ELOXEloxx PharmaceuticalsSCHEDULE 13G/A13G amendment
- DFTXDefinium TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- DBVTDBV TechnologiesSCHEDULE 13G/A13G amendment
- CINGCingulateReleaseCingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission
- CINGCingulate8-KCurrent report: material agreement, results of operations · EX-99.1
- CINGCingulate424B3Prospectus (resale / update)
- CINGCingulate10-QQuarterly report
- CAPRCapricor TherapeuticsSCHEDULE 13G/A13G amendment
- CAMPCamp4 TherapeuticsSCHEDULE 13G/A13G amendment
- BEAMBeam TherapeuticsSCHEDULE 13G/A13G amendment
- BCRXBiocryst PharmaceuticalsReleaseBioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
- BBOTBridgeBio Oncology TherapeuticsSCHEDULE 13G/A13G amendment
- AUTLAutolus TherapeuticsS-8Employee plan registration
- ARVNArvinasEFFECTRegistration effective
- ANTXAN2 TherapeuticsSCHEDULE 13G/A13G amendment
- ANTXAN2 TherapeuticsSCHEDULE 13G/A13G amendment
- AGIOAgios PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- ADCTADC TherapeuticsSCHEDULE 13G/A13G amendment
- ACTUActuate Therapeutics10-QQuarterly report→ BD updateThe Q3 10-Q lands with cash at $2.1M pre-offering, the over-allotment fully exercised today for an additional $1.53M, total net proceeds of $11.76M — and a second Nasdaq compliance clock (minimum bid price, deadline April 26, 2027) now running alongside the MVLS deficiency.
- ACETAdicet Bio8-KCurrent report: officer / director change
- ABSIAbsciSCHEDULE 13G/A13G amendment
- AARDAardvark TherapeuticsReleaseAardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates→ BD updateSummary on the 8-K
- AARDAardvark Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateAardvark's Q3 10-Q puts the first hard cash number on the board post-HERO termination ($60.3M, ~$13.6M Q3 burn), schedules the FDA meeting for Q1 2027, and adds a mavacamten-era clinical strategist to the board — all while the stock shed 12.5% on the session.
- AARDAardvark Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
Thursday, November 12157
- VRCAVerrica PharmaceuticalsReleaseVerrica Pharmaceuticals Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- VRCAVerrica Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings after the close: record YCANTH revenue of $5.7M with improving gross-to-net — the price-erosion bear case may be turning — but units dipped sequentially for the first time, and VP-315 just found a new target in Gorlin syndrome that could unlock an orphan pathway nobody was pricing in.
- VORVor BiopharmaReleaseVor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise→ BD updateSummary on the 8-K
- VORVor Biopharma8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1→ BD updateVor Bio acquired a next-generation long-acting BAFF/APRIL inhibitor (RC298) from RemeGen for ~$56M upfront, transforming the "single-asset bet" into a two-molecule franchise — but the market sold the news, and the dilution math deserves scrutiny before the 1H27 gMG binary.
- VIRVir BiotechnologyS-3ASRAutomatic shelf registration→ BD updateSummary on the 424B5
- VIRVir BiotechnologyReleaseVir Biotechnology Announces Proposed Public Offering→ BD updateSummary on the 424B5
- VIRVir Biotechnology424B5Prospectus supplement (offering)→ BD updateThree days after ECLIPSE 1 delivered its p<0.0001 verdict, Vir is raising capital in an underwritten public offering — the classic post-readout playbook, and a repeat of February's opportunistic raise into the Astellas pop. The stock bled 7.7% into today's close as the market digested the dilution; the offering terms land after the bell.
- TSHATaysha Gene TherapiesReleaseTaysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- TSHATaysha Gene Therapies8-KCurrent report: results of operations · EX-99.1→ BD updateThe PPQ manufacturing campaign — the gating CMC item I've flagged in every update since June — just passed, with all commercial batches meeting predefined specs and comparability criteria. Meanwhile the stock has drifted to $4.21, further below the $6.00 offering print, with the market seemingly unaware that the factory just delivered.
- TSHATaysha Gene Therapies10-QQuarterly report→ BD updateSummary on the 8-K
- TLSATiziana Life SciencesReleaseTiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED NOVEMBER 12, 2026
- TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
- STROSutro BiopharmaReleaseSutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlightsvia aggregator→ BD updateSummary on the 8-K
- STROSutro Biopharma8-KCurrent report: results of operations · EX-99.1→ BD updateThree months after STRO-004's debut data, STRO-006 has entered the clinic, Astellas has dosed the first patient in its second iADC program (triggering a $10M milestone), and cash sits at $142.2M — but the stock is down 55% from the August print and the market is clearly not impressed with thesis-intact quarterly updates.
- STROSutro Biopharma10-QQuarterly report→ BD updateSummary on the 8-K
- SLSSELLAS Life Sciences GroupReleaseSELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- SLSSELLAS Life Sciences Group8-KCurrent report: results of operations · EX-99.1
- SLSSELLAS Life Sciences Group10-QQuarterly report
- SGMTSagimet BiosciencesReleaseSagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
- SGMTSagimet Biosciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- SGMTSagimet Biosciences10-QQuarterly report
- RLMDRelmada TherapeuticsReleaseRelmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updatevia aggregator→ BD updateSummary on the 8-K
- RLMDRelmada Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED NOVEMBER 12, 2026, REGARDING CORPORATE UPDATE AND THIRD QUAR→ BD updateNDV-01's Phase 2 durability holds at 18 months — 86% of complete responders still in CR, zero Grade ≥3 AEs — while Relmada restores its "funded through 2029" guidance and signs a CMC manufacturing partner ahead of its year-end IND submission deadline.
- RLMDRelmada Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- RCKTRocket PharmaceuticalsReleaseRocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress→ BD updateSummary on the 8-K
- RCKTRocket Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateRocket's Q3 filing confirms RP-A701 has dosed its first patient in BAG3-DCM — the third leg of the cardiovascular stack is now live — while the securities class action saw its most dangerous claims dismissed with prejudice, leaving only a narrower dosing-timeline claim alive.
- RCKTRocket Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- QNRXQuoin Pharmaceuticals8-KCurrent report: shareholder vote
- PYPDPolyPid6-KForeign issuer report · EX-99.1 PRESS RELEASE ISSUED BY POLYPID LTD. ON NOVEMBER 11, 2026, TITLED "POLYPID PROVI
- PRQRProQR TherapeuticsReleaseProQR Announces Third Quarter 2026 Operating and Financial Results→ BD updateSummary on the 6-K
- PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateAX-0811 Cohorts 1 and 2 are now fully enrolled with January 2027 data locked in, the AX-0810 Cohort 3 readout has a named December 2026 conference venue, and the Q3 burn rate confirms the mid-2028 runway — but the stock has bled 32% since the last update and the Lilly registration statement remains unfiled nearly four months post-close.
- PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1→ BD updateSummary on the 6-K
- PRMEPrime Medicine8-KCurrent report: results of operations · EX-99.1
- PRMEPrime Medicine8-KCurrent report: material agreement
- PRMEPrime Medicine424B5Prospectus supplement (offering)
- PRMEPrime Medicine10-QQuarterly report
- PMNProMIS NeurosciencesSCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- PMNProMIS NeurosciencesReleaseProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing→ BD updateSummary on the 8-K
- PMNProMIS Neurosciences8-KCurrent report: results of operations · EX-99.1→ BD updateProMIS's Q3 numbers show burn decelerating to ~$8.2M/quarter as PRECISE-AD wraps patient visits, $44.1M cash still on hand, and a fresh 7.73% Schedule 13G from Adage Capital Management — a new institutional name that wasn't in the January PIPE syndicate — arriving the same day management leans into the ALTITUDE-AD failure as competitive differentiation ahead of Q1 2027 topline.
- PMNProMIS Neurosciences8-KCurrent report: Reg FD disclosure · EX-99.1→ BD updateSummary on the 8-K
- PMNProMIS Neurosciences10-QQuarterly report→ BD updateSummary on the 8-K
- PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
- PEPGPepGen8-KCurrent report: material agreement, other events · EX-99.1→ BD updateThe $125M offering priced at $5.00 — a slim premium to Tuesday's data-pop close, no warrants, and a clean institutional syndicate. Here's what the terms tell you about where the smart money is sizing this.
- PEPGPepGen424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
- OLMAOlema PharmaceuticalsReleaseOlema Oncology Announces Corporate Name Change
- OLMAOlema Pharmaceuticals8-KCurrent report: charter / bylaws / fiscal year, Reg FD disclosure, other events · EX-99.1
- NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026→ BD updateSummary on the 8-K
- NTLAIntellia Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateFour years of follow-up with zero waning: the lonvo-z durability data the FDA label depends on came in clean today, while the stock fell 7.5% — here's what readers need to know before the March 10 PDUFA.
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
- NKTRNektar TherapeuticsReleaseNektar Therapeutics Announces Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- NKTRNektar Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2026 RESULTS."→ BD updateQ3 burn accelerates to ~$70M — the highest quarter yet — as legal costs spike and the ZENITH machine ramps; the stock now trades at barely $0.3B above cash, within range of the revisit level I named in October, while ZENITH AA pulled forward to December.
- NGENNervGen PharmaReleaseNervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injuryvia aggregator→ BD updateNervGen just secured FDA Breakthrough Therapy Designation for NVG-291 in chronic spinal cord injury — a step above the Fast Track designation already in place, and the most meaningful regulatory de-risking event since the FDA aligned on the RESTORE protocol in April.
- MGTXMeiraGTxS-3ASRAutomatic shelf registration→ BD updateSummary on the 8-K
- MGTXMeiraGTxReleaseMeiraGTx Reports Third Quarter 2026 Financial and Operational Results→ BD updateSummary on the 8-K
- MGTXMeiraGTx8-KCurrent report: results of operations · EX-99.1→ BD updateBota-vec's MAA dossier is done and headed to the EMA in December, with the FDA BLA to follow in Q1 2027 — the filing strategy the prior writeup called unconfirmed has now been confirmed. Simultaneously, MeiraGTx filed a fresh $100M ATM shelf, resetting the dilution machinery right on schedule.
- MGTXMeiraGTx10-QQuarterly report→ BD updateSummary on the 8-K
- MESOMesoblast6-KForeign issuer report · EX-99.1→ BD updateThe November 10 AGM handed George his board seat (Voigtman elected 81% FOR), retired Burns and Rose from the board, and installed George as Interim COO at $500K/year — making the largest shareholder simultaneously the company's lender, board member, and now chief operating officer.
- MBRXMoleculin BiotechReleaseMoleculin Secures Australian Patent for Annamycin Formulation Technology
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- LGVNLongeveronReleaseLongeveron Announces 2026 Third Quarter Financial Results and Provides Business Updatevia aggregator→ BD updateSummary on the 8-K
- LGVNLongeveron8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE ISSUED BY THE COMPANY ON NOVEMBER 12, 2026→ BD updateThe Q3 10-Q puts $7.2M of cash against a runway that now ends in Q1 2027 — not Q4 2026 as last reported — but the burn math says the same thing: approximately one quarter of oxygen left. Meanwhile the CMO resigned and a second board member departed, draining governance capacity from a company already in strategic-alternatives mode and unable to hold its own earnings call.
- LGVNLongeveron10-QQuarterly report→ BD updateSummary on the 8-K
- LCTXLineage Cell TherapeuticsReleaseLineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease→ BD updateSummary on the 8-K
- LCTXLineage Cell TherapeuticsReleaseLineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- LCTXLineage Cell Therapeutics8-KCurrent report: material agreement, acquisition / disposition, results of operations · EX-99.1→ BD updateLineage closed today's acquisition of NeuroAirmid Therapeutics, adding HUNT1 — a pluripotent stem cell-derived neural therapy already dosed in 6 Huntington's patients, backed by $28M in CIRM funding — to its pipeline for a modest ~$4.7M at close, plus up to $48M in success-based milestones. The deal reshapes the "bench-wearing-a-program-name" bear case I called out in the deep dive, while adding new financial obligations that bear watching alongside Q2 2028 runway guidance.
- LCTXLineage Cell Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- KZIAKazia TherapeuticsReleaseKazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader
- KYTXKyverna TherapeuticsReleaseKyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- KYTXKyverna Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateKyverna crossed the BLA finish line for miv-cel in SPS — the milestone I've been tracking since March — but buried in the same press release is a decision to kill KYV-102, the rapid manufacturing program I called the "commercial unlock" for broad indications. The gate is open; the key to what's behind it just got thrown away.
- KYTXKyverna Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- KPRXKiora PharmaceuticalsReleaseKiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- KPRXKiora Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q drops a going-concern flag, cuts effective runway to "late 2027 excluding the $12.5M tech-transfer milestone," and starts a 16-day clock on the Tranche A-1 warrants — 7.86M shares at $1.94 that now expire November 28, 2026 with the stock sitting at $1.33.
- KPRXKiora Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- KODKodiak SciencesReleaseKodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- KODKodiak Sciences8-KCurrent report: results of operations · EX-99.1→ BD updateKodiak's Q3 10-Q — filed after today's close — confirms cash has fallen to $88.7M with going-concern language still in place, but the ATM faucet has already delivered $68.9M in net proceeds post-quarter, leaving $280.4M still available. With the Zenkuda BLA due by year-end and PEAK topline data weeks away, the treasury picture has finally started improving — but the December binary is here.
- KODKodiak Sciences10-QQuarterly report→ BD updateSummary on the 8-K
- IXHLIncannex Healthcare10-QQuarterly report→ BD updateIncannex's Q1 FY2027 10-Q reveals the cash burn has essentially vanished — net operating cash flow turned positive at +$0.5M vs. the -$9.2M quarter a year ago — extending the runway dramatically even as DReAMzz narrows its completion estimate to mid-2027.
- IRDOpus GeneticsSCHEDULE 13G/A13G amendment
- IPSCCentury TherapeuticsReleaseCentury Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
- IPSCCentury Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- IPSCCentury Therapeutics10-QQuarterly report
- IONSIonis PharmaceuticalsReleaseIonis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
- INKTMiNK Therapeutics8-KCurrent report: results of operations · EX-99.1
- INKTMiNK Therapeutics10-QQuarterly report
- IMRXImmuneeringReleaseImmuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients→ BD updateImmuneering signed its fourth pharma partnership (Astellas, CLDN18.2 combinations in pancreatic cancer) and announced a potentially registrational Phase 2 in anaplastic thyroid cancer — the first credible pipeline expansion that chips away at the single-asset concentration risk I've flagged since the original deep dive.
- IMRXImmuneeringReleaseImmuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer→ BD updateSummary on the release
- IMMXImmix BiopharmaReleaseImmix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
- IMMXImmix Biopharma8-KCurrent report: results of operations · EX-99.1
- IMMXImmix Biopharma10-QQuarterly report
- HROWHarrowSCHEDULE 13G/A13G amendment
- HROWHarrowReleaseHarrow to Participate in Two Investor Conferences in November
- HELPHelus PharmaSCHEDULE 13G/A13G amendment
- HELPHelus PharmaSCHEDULE 13G/A13G amendment
- GUTSFractyl HealthReleaseFractyl Health Reports Third Quarter 2026 Financial Results and Business Updates→ BD updateSummary on the 8-K
- GUTSFractyl Health8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q lands with $31.5M cash, a tighter covenant clock, a failed Nasdaq compliance cure (stock fell back below $1.00 after 16 days above), and meaningful new commercial catalysts — CPT code 1122T effective January 1, 2027 and a CMS RAPID pathway decision expected in early January that could unlock Medicare coverage for Revita ahead of a potential 2028 launch.
- GUTSFractyl Health10-QQuarterly report→ BD updateSummary on the 8-K
- GRCEGrace TherapeuticsReleaseGrace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update
- GRCEGrace Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- GRCEGrace Therapeutics10-QQuarterly report
- FDMT4D Molecular TherapeuticsRelease4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones→ BD updateSummary on the 8-K
- FDMT4D Molecular Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD update4DMT's Q3 10-Q shows burn held near $70M for the third straight quarter — the moderation test I set in August failed again — while cash sits at $375M and a new Chief Regulatory & Quality Officer joins ahead of the 4FRONT binary.
- FDMT4D Molecular Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- FBIOFortress BiotechReleaseJourney Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
- FATEFate TherapeuticsEFFECTRegistration effective
- FATEFate Therapeutics424B5Prospectus supplement (offering)
- EYPTEyePointReleaseEyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments→ BD updateSummary on the 8-K
- EYPTEyePoint8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q just delivered a going-concern qualification and confirmed that EyePoint sold nearly 23 million shares at $0.44 post-quarter — adding ~25% dilution at current prices to extend a runway that now only reaches late Q3 2027, while the stock sits below Nasdaq's $1.00 minimum-bid threshold with the delisting clock running.
- EYPTEyePoint10-QQuarterly report→ BD updateSummary on the 8-K
- EVMNEvommuneReleaseEvommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights→ BD update
- EVMNEvommune8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD update
- EVMNEvommune424B3Prospectus (resale / update)→ BD update
- EVMNEvommune10-QQuarterly report→ BD update
- ERASErascaReleaseErasca Reports Third Quarter 2026 Business Updates and Financial Results→ BD updateSummary on the 8-K
- ERASErasca8-KCurrent report: results of operations · EX-99.1→ BD updateErasca's Q3 earnings confirm a $947.8M war chest but also surface two new shareholder lawsuits and an accelerating burn rate — and the next ERAS-0015 data drop arrives in six days at the ENA Symposium oral plenary in Barcelona.
- ERASErasca10-QQuarterly report→ BD updateSummary on the 8-K
- ELDNEledon PharmaceuticalsReleaseEledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights→ BD updateSummary on the 8-K
- ELDNEledon Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q reveals cash has dropped to $69.7M with a visibly accelerating burn rate — and manufacturing costs alone nearly doubled year-over-year — while the FDA cleared the islet IND and BVF quietly converted another slug of preferred to common. The financing window is tighter than the headline runway implies.
- ELDNEledon Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- EIKNEikon TherapeuticsReleaseEikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates→ BD updateSummary on the 8-K
- EIKNEikon Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateEikon's Q3 10-Q extends runway guidance to Q1 2028 (up from "into 2H 2027"), narrows THE BIG ONE melanoma interim to 1H 2027, and shows $461.7M cash against a burn rate that has stabilized — but the stock dropped 9.4% anyway, and the dilution gap math still ends at zero cash before the confirmatory NSCLC trial completes.
- EIKNEikon Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED NOVEMBER 12, 2026
- DBVTDBV TechnologiesSCHEDULE 13G/A13G amendment
- DBVTDBV TechnologiesReleaseDBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years
- CYDYCytoDynReleaseCytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors→ BD updateA returning anonymous investor puts $5M into CYDY at $0.24/share — no warrants, no placement agent fee — a structurally cleaner raise than the last two, but still a rounding error against $7.7M/quarter burn and a 383.9M-share warrant ceiling.
- CRNXCrinetics PharmaceuticalsSCHEDULE 13G/A13G amendment
- CRDLCardiol TherapeuticsReleaseRecurrent Pericarditis: Through the Eyes of the Physicians Treating It
- CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- CGEMCullinan TherapeuticsReleaseNew Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
- CBIOCrescent BiopharmaReleaseCrescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights→ BD updateSummary on the 8-K
- CBIOCrescent Biopharma8-KCurrent report: results of operations · EX-99.1→ BD updateCrescent's Q3 earnings confirm the first APOLLO patient dosed and reveal the ATM tapped for $11.1M in Q3 — two named watch-list items closed in a single quarter, with $289.4M cash still on hand and the Q1 2027 ASCEND binary closing fast.
- CBIOCrescent Biopharma10-QQuarterly report→ BD updateSummary on the 8-K
- CATXPerspective TherapeuticsSCHEDULE 13D/A13D amendment→ BD updateLantheus has filed its exit amendment, selling 3M shares at $0.80 on November 10 to drop below 5% — the strategic overhang that has weighed on CATX since September is effectively resolved, leaving the EOP2 meeting as the next real catalyst.
- CAMPCamp4 TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CADLCandel TherapeuticsReleaseCandel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights→ BD updateSummary on the 8-K
- CADLCandel Therapeutics8-KCurrent report: other events→ BD updateCandel pushed its aglatimagene BLA from Q4 2026 to "mid-2027" — a 6-9 month slip that delays the entire approval timeline and tightens an already razor-thin cash runway, while simultaneously reopening a fresh $50M ATM program after exhausting the prior one.
- CADLCandel Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateSummary on the 8-K
- CADLCandel Therapeutics424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- CADLCandel Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- BLTEBelite BioReleaseBelite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update→ BD updateSummary on the 6-K
- BLTEBelite Bio6-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateThe FDA has confirmed it will not convene an advisory committee for tinlarebant's STGD1 NDA — the single most telling signal that the agency isn't escalating the functional-benefit debate, removing a tail risk I'd flagged explicitly and clearing the regulatory runway to the February 12, 2027 PDUFA date.
- BDTXBlack Diamond TherapeuticsReleaseBlack Diamond Therapeutics to Participate in Upcoming Investor Conferences
- AUTLAutolus TherapeuticsSCHEDULE 13G/A13G amendment
- ATHEAlterity TherapeuticsReleaseAlterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conferencevia aggregator
- ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- APVOAptevo TherapeuticsSCHEDULE 13G/A13G amendment
- APVOAptevo TherapeuticsReleaseAptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds
- APVOAptevo TherapeuticsPRE 14APRE 14A
- APVOAptevo Therapeutics8-KCurrent report: material agreement, unregistered sale of equity, other events · EX-99.1
- ANABAnaptysBioReleaseAnaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
- ANABAnaptysBio8-KCurrent report: results of operations · EX-99.1
- ANABAnaptysBio10-QQuarterly report
- ALTAltimmuneReleaseAltimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology→ BD updateSummary on the 8-K
- ALTAltimmuneReleaseAltimmune Announces Third Quarter 2026 Financial Results and Business Update→ BD updateSummary on the 8-K
- ALTAltimmune8-KCurrent report: results of operations · EX-99.1→ BD updateALT dropped 16.6% on Q3 earnings day despite solid science and $480M in cash — the market is pricing accelerating PERFORMA burn, a CMO selling plan, and a stock now 46% below the April offering price, even as the IMPACT data earns a Lancet publication and the December AUD FDA meeting looms.
- ALTAltimmune10-QQuarterly report→ BD updateSummary on the 8-K
- ALMSAlumisReleaseAlumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updatesvia aggregator
- ALMSAlumis8-KCurrent report: results of operations · EX-99.1
- ALMSAlumis10-QQuarterly report
- ALDXAldeyra TherapeuticsSCHEDULE 13G/A13G amendment
- AKTSAktis OncologyReleaseAKTIS ONCOLOGY REPORTS THIRD-QUARTER FINANCIAL RESULTS AND HIGHLIGHTS CLINICAL TRIAL PROGRESS→ BD updateSummary on the 8-K
- AKTSAktis Oncology8-KCurrent report: results of operations · EX-99.1→ BD updateThe Actinium bottleneck just cracked open: Aktis operationalized its in-house GMP facility and opened backfill cohorts in both lead trials — the strongest signal yet that therapeutic doses have been selected — while the stock sits 32% below its post-ASCO high ahead of the Q1 2027 binary.
- AKTSAktis Oncology10-QQuarterly report→ BD updateSummary on the 8-K
- ACRSAclaris TherapeuticsReleaseAclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference
- ABSIAbsciS-3ASRAutomatic shelf registration→ BD updateSummary on the 8-K
- ABSIAbsciReleaseAbsci Reports Business Updates and Third Quarter 2026 Financial and Operating Resultsvia aggregator→ BD updateSummary on the 8-K
- ABSIAbsciReleaseAbsci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipelinevia aggregator→ BD updateSummary on the 8-K
- ABSIAbsci8-KCurrent report: results of operations, other events · EX-99.1→ BD updateQ3 numbers are in, the December PoC readout is weeks away, and ABSI dropped -9.7% on news that actually strengthens the runway thesis — plus a new CCO hire and detailed STORYLINE trial design for endometriosis.
- ABSIAbsci10-QQuarterly report→ BD updateSummary on the 8-K
Wednesday, November 1119
- WVEWave Life SciencesReleaseWave Life Sciences to Present at Jefferies Global Healthcare Conference in London
- VNDAVanda PharmaceuticalsReleaseNEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Weekvia aggregator
- RXRXRecursion PharmaceuticalsReleaseRecursion to Participate in Upcoming Investor Conferences
- RAREUltragenyx PharmaceuticalReleaseUltragenyx to Participate at Investor Conferences in London
- QTTBQ32 BioReleaseQ32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
- PYPDPolyPidReleasePolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results→ BD updateSeventeen days from the November 28 PDUFA, PolyPid's Q3 print confirms labeling discussions are "underway and on track," the NTAP application is filed, a new named pipeline asset (PD01B, diabetic foot infections) has emerged, and the balance sheet holds ~$30.5M pro forma — with the stock up 30% since my last update and warrant overhang dynamics shifting.
- PEPGPepGenReleasePepGen Announces Pricing of $125 Million Public Offering
- ONCYOncolytics BiotechReleaseOncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma
- NRXPNRX PharmaceuticalsReleaseNRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage→ BD updateNRx just launched its preservative-free ketamine with a 17-person sales force covering 80% of the U.S. market, targeting first shipments in January 2027 and projecting >50% gross margins — the first concrete commercial data point since the October 30 ANDA approval.
- NRIXNurix TherapeuticsReleaseNurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
- NKTXNkartaReleaseNkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
- NKTRNektar TherapeuticsReleaseNektar Therapeutics to Participate in Two Investor Conferences in November
- KODKodiak SciencesReleaseKodiak Sciences to Present at Three Upcoming Investor Conferences
- INKTMiNK TherapeuticsReleaseMiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies→ BD updateMiNK's Q3 drops three genuine thesis movers: ARPA-H selected agenT-797 for a room-temperature cell-therapy program (up to $87M program-wide), the named-patient program generated the company's first-ever product revenue, and the randomized ARDS readout slipped to 2H2027 — adding a full year to the binary-event clock.
- IBRXImmunityBioReleaseNew U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care
- DYNDyne TherapeuticsReleaseDyne Therapeutics to Participate in Upcoming Investor Conference
- CMPSCOMPASS PathwaysReleaseCompass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
- APVOAptevo TherapeuticsReleaseAptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds→ BD updateAptevo induced warrant holders to exercise at a repriced $1.08 strike — down 73% from the $4.03 strike set just three months ago — for $3.0M gross and issued 13.9M new warrants in return, while the stock cratered nearly 30% on the news.
- ACIUAC ImmuneReleaseAC Immune to Present at Jefferies Global Healthcare Conference 2026
Tuesday, November 10109
- VSTMVerastemSCHEDULE 13GPassive >5% holder (13G)
- VRDNViridian TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- VRCAVerrica PharmaceuticalsReleaseVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
- VORVor BiopharmaReleaseVor Bio To Participate in 2026 Jefferies Global Healthcare Conference
- VNDAVanda PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- VIRVir BiotechnologySCHEDULE 13GPassive >5% holder (13G)
- VERAVera TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- UPBUpstream BioReleaseUpstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progressvia aggregator
- UPBUpstream Bio8-KCurrent report: results of operations · EX-99.1
- UPBUpstream Bio10-QQuarterly report
- TYRATyra BiosciencesReleaseTyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
- TYRATyra Biosciences8-KCurrent report: results of operations · EX-99.1
- TYRATyra Biosciences10-QQuarterly report
- TTRXTurn Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1 INVESTOR PRESENTATION, DATED NOVEMBER 10, 2026
- SYRESpyre TherapeuticsReleaseSpyre Therapeutics to Participate in Upcoming Investor Conferences
- SRPTSarepta TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- SNDXSyndax PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- SLSSELLAS Life Sciences GroupSCHEDULE 13GPassive >5% holder (13G)
- SLDBSolid BiosciencesReleaseSolid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conferencevia aggregator
- SIONSionna TherapeuticsReleaseSionna Therapeutics Reports Third Quarter 2026 Financial Results
- SIONSionna Therapeutics8-KCurrent report: results of operations · EX-99.1
- SIONSionna Therapeutics10-QQuarterly report
- RXRXRecursion PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- REPLReplimune GroupSCHEDULE 13GPassive >5% holder (13G)
- RAREUltragenyx PharmaceuticalSCHEDULE 13GPassive >5% holder (13G)
- QUITAchieve Life SciencesReleaseAchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates
- QUITAchieve Life Sciences8-KCurrent report: results of operations · EX-99.1
- QUITAchieve Life Sciences10-QQuarterly report
- PRMEPrime Medicine8-KCurrent report: results of operations, other events · EX-99.1
- PRMEPrime Medicine424B5Prospectus supplement (offering)
- PMVPPMV PharmaceuticalsReleasePMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights→ BD updateSummary on the 8-K
- PMVPPMV Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q formally lifts the going-concern flag, extends cash runway to Q1 2028, and PMV hired its first Chief Commercial Officer — signaling the team now believes approval is a matter of when, not if, with the pivotal PYNNACLE readout at ENA 2026 still ahead.
- PMVPPMV Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- PEPGPepGenReleasePepGen Announces Proposed $125.0 Million Public Offering of Common Stock→ BD updateSummary on the 8-K
- PEPGPepGenReleasePepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights→ BD updateSummary on the 8-K
- PEPGPepGenReleasePepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures→ BD updateSummary on the 8-K
- PEPGPepGen8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1→ BD updateThe binary 10 mg/kg FREEDOM2 readout delivered — 46.5% mean splicing correction on ITT, functional improvements across myotonia, grip and mobility, clean safety, and no outlier exclusions needed. The stock nearly doubled on the news, and PepGen immediately launched a $125M follow-on offering after the close.
- PEPGPepGen424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- PEPGPepGen10-QQuarterly report→ BD updateSummary on the 8-K
- PALIPalisade BioReleasePalisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs→ BD updateSummary on the 8-K
- PALIPalisade Bio8-KCurrent report: results of operations · EX-99.1→ BD updateASCENTRA-UC dosed its first patient on October 27 — the binary is now live — while Q3 numbers confirm cash burn is tracking to model and a newly disclosed BIOSECURE Act / WuXi STA supply risk introduces a CMC variable I hadn't quantified before.
- PALIPalisade Bio10-QQuarterly report→ BD updateSummary on the 8-K
- OVIDOvid TherapeuticsS-3Shelf registration→ BD updateSummary on the 8-K
- OVIDOvid TherapeuticsReleaseOvid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- OVIDOvid Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings pull the two nearest catalysts — the OV329 photosensitivity readout and OV4071 Phase 1 topline — into the same quarter (Q1 2027), while quarterly R&D burn hits its highest level yet at $15.7M and the ATM program switches from Cowen to Cantor Fitzgerald.
- OVIDOvid Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- OMEROmerosReleaseOmeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
- OLMAOlema PharmaceuticalsReleaseOlema Oncology Reports Third Quarter 2026 Financial and Operating Results→ BD updateSummary on the 8-K
- OLMAOlema Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateOlema's Q3 10-Q reaffirms OPERA-01 reads in Q1 2027 with $413.8M in cash — more runway than I estimated — but the burn rate accelerated sharply and December SABCS data drops are now on the calendar for three combination programs.
- OLMAOlema Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- OCGNOcugenReleaseOcugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
- OCGNOcugen8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- NTLAIntellia TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- NTLAIntellia TherapeuticsReleaseIntellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
- NKTRNektar TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- MBXMBX BiosciencesS-8Employee plan registration
- MBRXMoleculin BiotechReleasePreclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- LXEOLexeo TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- LQDALiquidiaReleaseLiquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference→ BD updateSummary on the 8-K
- LQDALiquidia8-KCurrent report: results of operations, other events · EX-99.1 EXHIBIT 99.1→ BD updateQ3 net product sales of $222.7M came in well ahead of expectations and October shipments hit an all-time high — the first commercial print post-settlement shows the PAH business is holding, though the cash picture is tighter than it looked before the 10-Q revealed $105.4M in restricted collateral.
- LQDALiquidia10-QQuarterly report→ BD updateSummary on the 8-K
- LEGNLegend BiotechReleaseLegend Biotech Reports Third Quarter 2026 Results and Recent Highlights→ BD updateSummary on the 6-K
- LEGNLegend Biotech6-KForeign issuer report · EX-99.1→ BD updateQ3 earnings: CARVYKTI hit ~$710M in net trade sales (+36% YoY), collaboration gross margin held at ~58.4%, and the J&J Funding Advance is now down to $44.1M from $319.1M — the cash-flow inflection is essentially complete. FDA also cleared the LB2501 IND. Yet the stock cratered 16% on the print, and the reason matters: December 23 is six weeks away.
- KURAKura OncologyS-3ASRAutomatic shelf registration→ BD updateSummary on the 8-K
- KURAKura OncologyReleaseKura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update→ BD updateSummary on the 8-K
- KURAKura Oncology8-KCurrent report: results of operations · EX-99.1→ BD updateKURA's Q3 earnings arrived with a 53% sequential revenue beat and majority class share intact — but the stock has cratered 37% since my last update, and a new Oberland debt deal carrying a royalty participation on KOMZIFTI sales changes the financial picture materially. Here's what changed and what it means for the thesis.
- KURAKura Oncology10-QQuarterly report→ BD updateSummary on the 8-K
- IRDOpus GeneticsReleaseOpus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update→ BD updateSummary on the 8-K
- IRDOpus Genetics8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q reveals the warrant overhang I've called the structural bear case nearly evaporated — 18.5M warrants exercised in Q3, only 2.86M remain and all are called — while CEO Magrath terminated his sell plan the day after the BEST1 print and the down-round ratchet expired unused, materially changing the balance-sheet and insider-signal picture ahead of the Q1 2027 Cohort 2 readout.
- IRDOpus Genetics10-QQuarterly report→ BD updateSummary on the 8-K
- IONSIonis PharmaceuticalsReleaseIonis to present at upcoming investor conferences
- IMTXImmaticsReleaseImmatics Announces Third Quarter 2026 Financial Results and Business Update
- IMTXImmatics6-KForeign issuer report · EX-99.1
- IBRXImmunityBioReleaseImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
- GOSSGossamer BioReleaseGossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- GOSSGossamer Bio8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q lands with both 2027 and 2030 notes classified as current liabilities, cash down to $51.2M against a $40M monthly covenant floor, and the $125M second tranche expiring December 31 — the FDA acceptance clock has never mattered more.
- GOSSGossamer Bio10-QQuarterly report→ BD updateSummary on the 8-K
- GERNGeronSCHEDULE 13GPassive >5% holder (13G)
- GANXGain TherapeuticsReleaseGain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update→ BD updateSummary on the 8-K
- GANXGain Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateThe Schwartzberg motion-to-dismiss denial puts the CEO fraud lawsuit into active discovery — a new escalation not in any prior post — while cash hits $11.7M, the ATM prints at $1.58, and the stock is down 37% since the October Korea readout.
- GANXGain Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- FDMT4D Molecular TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- FBIOFortress BiotechReleaseFortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
- FATEFate TherapeuticsReleaseFate Therapeutics Presents New FT819 Data At ACR Convergence 2026 Highlighting Meaningful Clinical Responses In Lupus Without The Use Of Conditioning Chemotherapy→ BD updateACR delivered encouraging no-conditioning responses in extrarenal lupus — but the pivotal-regimen CRR count at 900M + bendamustine is still missing, triggering the PASS condition I named explicitly in both the deep dive and my November 5 update.
- EVMNEvommuneSCHEDULE 13D/A13D amendment
- CYDYCytoDynReleaseCytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer→ BD update
- CUECue BiopharmaSCHEDULE 13G/A13G amendment
- CTMXCytomX TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CRVSCorvus PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- COYACoya TherapeuticsReleaseCoya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update→ BD updateSummary on the 8-K
- COYACoya Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateCOYA's Q3 burn rate surged to ~$10M — well above the $7.5M/quarter assumption in the original PASS verdict — compressing the cash cushion at the ALSTARS readout and triggering a formal going-concern disclosure for the first time. The 137-patient final enrollment (vs. 120 planned) is a mild bright spot for statistical power, but it's not enough to offset the burn acceleration.
- COYACoya Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- CMPXCompass TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CMMBChemomab TherapeuticsSCHEDULE 13DActivist / >5% holder (13D)
- CMMBChemomab TherapeuticsDEFA14AProxy soliciting material
- CLRBCellectar BiosciencesReleaseCellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates LEARN MORE→ BD updateSummary on the 8-K
- CLRBCellectar Biosciences8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateQ3 numbers confirm the burn is accelerating toward $8M/quarter while the cash clock ticks to Q2 2027 — but new IWWM data (87.5% ORR, 100% CBR, n=24 post-BTKi) and a Q4 2026 CLR 125 data signal are the most important developments hiding inside a routine quarterly filing.
- CLRBCellectar Biosciences10-QQuarterly report→ BD updateSummary on the 8-K
- CINGCingulateReleaseShane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King→ BD updateSummary on the 8-K
- CINGCingulate8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateCingulate finally puts a date on the CTx-1301 resubmission — December 2026 to January 2027 — and says manufacturing work is "substantially completed," moving the story from indefinite to calendared; a Q3 2027 commercial launch target follows, but the Class 1 vs. Class 2 FDA review clock remains undisclosed, keeping the approval date range wide.
- CGENCompugenReleaseCompugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit
- CGEMCullinan TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- CGEMCullinan Therapeutics8-KCurrent report: results of operations · EX-99.1
- CGEMCullinan Therapeutics10-QQuarterly report
- CATXPerspective TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CAPRCapricor TherapeuticsReleaseCapricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- CAPRCapricor Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateWith the November 22 PDUFA twelve days away, Capricor's Q3 10-Q shows cash down to ~$198.5M, a 10% workforce cut, the NS arbitration pushed to mid-2027, and an AHA award for the cardiac data — the last status check before the binary.
- CAPRCapricor Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- BMEABiomea FusionReleaseBiomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights→ BD updateSummary on the 8-K
- BMEABiomea FusionReleaseBiomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026→ BD updateSummary on the 8-K
- BMEABiomea Fusion8-KCurrent report · EX-99.1→ BD updateThe Q3 10-Q lands with $26.8M cash, a formal going-concern warning that now explicitly states the company cannot fund twelve months of operations, and a stock sitting at $0.55 — well below Nasdaq's $1.00 minimum bid threshold. The menin brake thesis is intact heading into the Q1 2027 COVALENT-211 readout, but the cost of capital to get there has never been higher.
- BMEABiomea Fusion10-QQuarterly report→ BD updateSummary on the 8-K
- BEAMBeam TherapeuticsReleaseBeam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease→ BD updateBEACON's pivotal interim cleared the bar — 31 of 49 patients free from severe VOCs for 12 straight months — and the BLA is coming year-end. The stock sold off 6.9% anyway, repricing a permission slip, not a commercial win.
- BDTXBlack Diamond TherapeuticsReleaseBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update→ BD updateSummary on the 8-K
- BDTXBlack Diamond Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateBlack Diamond's October 1 FDA meeting produced a brain-metastases-enriched Phase 3 design with CNS-ORR as the accelerated approval endpoint — a narrower, potentially faster path than feared — but the stock sold off 14% because the partner who would fund it still doesn't exist.
- BDTXBlack Diamond Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- BCRXBiocryst PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- BCAXBicara TherapeuticsS-8Employee plan registration
- BBOTBridgeBio Oncology TherapeuticsReleaseBBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress→ BD update
- BBOTBridgeBio Oncology Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD update
- BBOTBridgeBio Oncology Therapeutics10-QQuarterly report→ BD update
- AUTLAutolus TherapeuticsSCHEDULE 13D/A13D amendment→ BD updateSummary on the 8-K
- AUTLAutolus TherapeuticsReleaseAUTOLUS THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATES→ BD updateSummary on the 8-K
- AUTLAutolus TherapeuticsReleaseAUTOLUS THERAPEUTICS PRESENTS LONGER-TERM FOLLOW UP DATA FROM CARLYSLE TRIAL AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2026→ BD updateSummary on the 8-K
- AUTLAutolus Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateQ3 2026 prints another clean beat — $41.2M revenue, 57% gross margin, guidance raised to ≥$150M — while CARLYSLE lupus data expand to 15 patients with 100% DORIS at ≥6 months and 66.7% complete renal response, and the BOBCAT MS readout slips again to 2H 2027.
- AUTLAutolus Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- ARDXArdelyxReleaseArdelyx to Participate at the Jefferies Global Healthcare Conference in London
- ANROAlto Neuroscience8-KCurrent report: results of operations · EX-99.1
- ANROAlto Neuroscience10-QQuarterly report
- ANABAnaptysBioReleaseAnaptys Announces Participation in Upcoming Investor Conferences
- ALTAltimmuneSCHEDULE 13GPassive >5% holder (13G)
- ALLOAllogene TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ADMAAdma BiologicsSCHEDULE 13GPassive >5% holder (13G)
- ADCTADC TherapeuticsS-3Shelf registration
- ACRVAcrivon Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
Monday, November 9153
- ZYMEZymeworksReleaseZymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results 2026 financial guidance raised to a total revenue range of $337 million to $351 million (previously between $278 mi→ BD updateSummary on the 8-K
- ZYMEZymeworks8-K/ACurrent report (amended) · EX-99.3→ BD updateSummary on the 8-K
- ZYMEZymeworks8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateQ3 earnings landed after the close with a guidance raise, the HERIZON-GEA-01 final OS readout (median 27 months, HR 0.65 with the triplet), and pasritamig Phase 1 combination data showing a 73% PSA50 response — the flywheel is accelerating on multiple fronts simultaneously.
- ZYMEZymeworks10-QQuarterly report→ BD updateSummary on the 8-K
- ZURAZura BioReleaseZura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa→ BD updateSummary on the 8-K
- ZURAZura Bio8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1→ BD updateTibuSHIELD failed across every endpoint — primary AN count miss, HiSCR50 miss, HiSCR75 miss — with placebo response rates so high the drug couldn't separate, and HS development is now discontinued. The bear case the original writeup laid out has arrived: the BAFF arm never earned its keep, and the stock has crashed ~70% today to reflect it.
- ZNTLZentalis PharmaceuticalsReleaseZentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates→ BD updateSummary on the 8-K
- ZNTLZentalis Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateZNTL's Q3 10-Q confirms $228.9M cash (runway into 1H 2028), Part 2c enrollment completing this month — the trigger I named as the "add" signal — but the company's new language on accelerated approval reveals a meaningful regulatory hedge that investors should not miss.
- ZNTLZentalis Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- ZBIOZenas BioPharmaReleaseZenas BioPharma to Present at the Jefferies London Global Healthcare Conference
- XNCRXencorReleaseXencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657→ BD updatePlamotamab's first RA patient data show >99% B-cell depletion and a >50% drop in disease activity scores at the highest dose tested — the first clinical efficacy signal from Xencor's autoimmune B-cell-depletion franchise, arriving while XmAb657 clears healthy-volunteer safety hurdles ahead of Q1 2027 patient enrollment.
- XENEXenon PharmaceuticalsS-8Employee plan registration→ BD updateSummary on the 8-K
- XENEXenon PharmaceuticalsReleaseXenon Reports Q3 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- XENEXenon Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateX-NOVA2 MDD data moves to December 2026 — the coin flip just got a lot closer — and Xenon quietly announced X-FIRST, a trial designed to push azetukalner into earlier lines of therapy and expand the addressable market well beyond the refractory epilepsy label.
- XENEXenon Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- VRDNViridian TherapeuticsReleaseViridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing→ BD updateSummary on the 8-K
- VRDNViridian Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateVRDN-008's phase 1 data landed this morning with a 74% peak IgG reduction, a 15–18 day half-life (up to 6x first-gen Fc fragments), and a clean safety profile — clearing the bar I called "the sleeper asset" and opening a direct path to a registrational MG trial in mid-2027.
- VKTXViking TherapeuticsReleaseViking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
- VIRVir Biotechnology8-KCurrent report: Reg FD disclosure, other events→ BD updateECLIPSE 1 met every endpoint: 79% of patients hit undetectable virus at Week 48 (p<0.0001), all 124 patients completed treatment, and exploratory data from SOLSTICE suggest 10/10 patients who stopped dosing after 96 weeks of viral suppression maintained sustained viral response — a potential cure signal for the most severe form of viral hepatitis.
- TTRXTurn TherapeuticsS-3Shelf registration→ BD updateSummary on the 8-K
- TTRXTurn TherapeuticsS-3Shelf registration→ BD updateSummary on the 8-K
- TTRXTurn TherapeuticsReleaseTurn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- TTRXTurn Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE, DATED NOVEMBER 9, 2026→ BD updateThe GEM facility finally fired — a $2.72M draw-down at ~$10/share pricing — and Turn simultaneously filed a $150M shelf + $50M ATM agreement with TD Cowen, while the Q3 10-Q reveals an October 29 GEM draw-down notice and a quietly disclosed PJT Partners strategic advisory engagement ahead of the Q1 2027 topline.
- TTRXTurn Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- TNGXTango TherapeuticsReleaseTango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
- TNGXTango Therapeutics8-KCurrent report: results of operations · EX-99.1
- TNGXTango Therapeutics10-QQuarterly report
- TLSATiziana Life SciencesReleaseTiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast
- TLSATiziana Life SciencesReleaseTiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED NOVEMBER 9, 2026
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED NOVEMBER 9, 2026
- TGTXTg TherapeuticsReleaseTG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance→ BD updateSummary on the 8-K
- TGTXTg Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateTG raised full-year guidance to ~$1 billion — a third consecutive raise — while Q3 operating income of $85.9M signals that the margin compression from SubQ build costs is turning into real operating leverage. The "buying share by the hour" thesis is compounding faster than modeled, but the stock has re-rated aggressively to match.
- TGTXTg Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- TECXTectonic TherapeuticReleaseWATERTOWN, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeut
- STROSutro BiopharmaSCHEDULE 13GPassive >5% holder (13G)
- SPRBSpruce BiosciencesReleaseSpruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates→ BD updateSummary on the 8-K
- SPRBSpruce BiosciencesReleaseSpruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences→ BD updateSummary on the 8-K
- SPRBSpruce Biosciences8-KCurrent report: results of operations · EX-99.1→ BD updateWith a December BLA submission weeks away, Spruce just spun out its CAH program into a separate company, flagged a going-concern qualification, and renegotiated its debt — making SPRB a leaner, higher-stakes pure-play on TA-ERT and the FDA's surrogate-endpoint call.
- SPRBSpruce Biosciences10-QQuarterly report→ BD updateSummary on the 8-K
- SIONSionna TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- SEPNSepternaReleaseSepterna Highlights Business Progress and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- SEPNSepterna8-KCurrent report: results of operations · EX-99.1→ BD updateSepterna's Q3 earnings arrive with a double catalyst: SEP-204 formally selected as TSHR development candidate (new preclinical animal data at ATA), and Q3 financials reveal the burn is accelerating — $36.6M R&D in a single quarter — alongside a fresh wave of executive 10b5-1 selling plans from the CEO, CFO, and COO.
- SEPNSepterna10-QQuarterly report→ BD updateSummary on the 8-K
- RVPHReviva PharmaceuticalsDEF 14AProxy statement
- RVPHReviva PharmaceuticalsARSAnnual report to shareholders
- REPLReplimune GroupSCHEDULE 13G/A13G amendment
- QUITAchieve Life SciencesReleaseAchieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
- PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
- PALIPalisade BioSCHEDULE 13G/A13G amendment
- ORKAOruka TherapeuticsReleaseOruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- ORKAOruka Therapeutics10-QQuarterly report
- ONCYOncolytics BiotechReleasePelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
- ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
- OCSOculis HoldingReleaseOculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
- NKTXNkartaReleaseNkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence→ BD updateSummary on the 8-K
- NKTXNkarta8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateNKX019's first efficacy data in autoimmune patients landed this morning — 83% response in myositis, 71–86% in systemic sclerosis, zero CRS/ICANS/GVHD across 40 patients — clearing the bar I set, yet the stock is trading lower. Here's what the data actually says and why the market got this wrong.
- NGNENeurogeneReleaseNeurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates
- NGNENeurogene8-KCurrent report: results of operations · EX-99.1
- NGNENeurogene10-QQuarterly report
- NBPNovaBridge BiosciencesReleaseNovaBridge Biosciences to Participate in Upcoming Investor Conferences
- MDNAFMedicenna TherapeuticsReleaseMedicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved Therapies→ BD updateThe SITC 2026 oral slot delivered: 40% ORR and 80% disease control in checkpoint-refractory GI cancers with durability data not yet reached — the strongest MDNA11 readout to date, arriving exactly when the thesis said it needed to.
- MBXMBX Biosciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- MBXMBX Biosciences10-QQuarterly report
- MAZEMaze TherapeuticsReleaseMaze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights→ BD updateSummary on the 8-K
- MAZEMaze Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateHORIZON just enrolled 50+ patients across all three AMKD cohorts — more than triple the initial 15-patient interim cut and well above the 10–15/cohort target — setting up a materially stronger dataset for the early-2027 readout than the writeup modeled.
- MAZEMaze Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- MAIAMAIA Biotechnology10-QQuarterly report→ BD updateThe Q3 10-Q lands with $21.3M cash, a burn rate that's converging on the same ~$6M quarterly pace as Q2, the Digital Asset Treasury Plan still "on hold" for a third straight quarter, and the Wainwright hearing now pushed to February 2027. The science is unchanged — but the financial runway math just got tighter.
- LRMRLarimar TherapeuticsReleaseLarimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia→ BD updateSummary on the 8-K
- LRMRLarimar Therapeutics8-KCurrent report: results of operations, other events · EX-99.1→ BD updateLarimar completed its rolling BLA submission for nomlabofusp after the close today — the milestone I've called "The Big One" since the original deep dive — with FDA acceptance targeted for early 2027 and Q3 cash at $128.7M as the runway clock ticks toward a mid-2027 approval decision.
- KYTXKyverna TherapeuticsReleaseKyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
- JANXJanux TherapeuticsReleaseJanux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease→ BD updateThe JANX011 autoimmune lottery ticket hit: >90% B-cell depletion, Grade 1-only CRS, zero SAEs across 25 healthy volunteers — yet JANX closed down 27.6% on the day. The data said yes; the market said sell.
- IONSIonis PharmaceuticalsReleaseIonis reports third quarter 2026 financial results and highlights progress on key programs→ BD updateSummary on the 8-K
- IONSIonis Pharmaceuticals8-KCurrent report: results of operations · EX-99 EXHIBIT 99.1→ BD updateTRYNGOLZA's Q3 print landed at $9.3 million — well below the $20 million floor I said would convert this thesis to a Pass — and Ionis simultaneously cut full-year guidance from $100–110M to ~$50M. The stock dropped 21% on the day, and Roche quietly terminated two additional collaborations.
- IONSIonis Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- IMVTImmunovantS-3ASRAutomatic shelf registration→ BD update
- IMVTImmunovantReleaseRoivant 2Q 2026 Earnings Call→ BD update
- IMVTImmunovantReleaseImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026→ BD update
- IMVTImmunovant8-KCurrent report: results of operations · EX-99.1→ BD update
- IMVTImmunovant10-QQuarterly report→ BD update
- IMRXImmuneeringReleaseImmuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
- IMRXImmuneering8-KCurrent report: officer / director change
- IMNMImmunomeS-3ASRAutomatic shelf registration
- IMNMImmunomeS-3ASRAutomatic shelf registration
- IMNMImmunomeReleaseImmunome Reports Third Quarter 2026 Financial Results and Provides Business Updatevia aggregator
- IMNMImmunome8-KCurrent report: results of operations · EX-99.1
- IMNMImmunome10-QQuarterly report
- IMCRImmunocoreSCHEDULE 13GPassive >5% holder (13G)
- IMCRImmunocoreReleaseImmunocore to present at upcoming investor conferences
- IBRXImmunityBioReleaseImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ→ BD updateSummary on the 8-K
- IBRXImmunityBioReleaseImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial→ BD updateSummary on the 8-K
- IBRXImmunityBioReleaseImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million→ BD updateSummary on the 8-K
- IBRXImmunityBio8-KCurrent report: results of operations · EX-99.1→ BD updateANKTIVA just won the registrational trial that was supposed to define the entire bull case — QUILT-2.005 Cohort A met its primary endpoint in BCG-naïve bladder cancer — yet the stock is down 17% on the day earnings landed alongside it. Here's why the market is wrong to shrug, and what matters next.
- IBRXImmunityBio8-KCurrent report: Reg FD disclosure · EX-99.1→ BD updateSummary on the 8-K
- IBRXImmunityBio10-QQuarterly report→ BD updateSummary on the 8-K
- HROWHarrowReleaseHarrow Announces Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- HROWHarrow8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateHarrow's Q3 print landed at $99.3M — clearing the bar I set — but management simultaneously slashed the EBITDA guide by roughly 60% and the 10-Q formally confirmed the Novaliq/TYRVAYA conflict remains unresolved, with no consent obtained. The revenue ramp is real; the profit ramp is not what was promised.
- HROWHarrow10-QQuarterly report→ BD updateSummary on the 8-K
- GPCRStructure TherapeuticsReleaseStructure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights→ BD updateSummary on the 8-K
- GPCRStructure Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateStructure Therapeutics' Q3 10-Q reveals a $134.6M R&D quarter — 128% above prior year — while burying a CTO departure effective November 13 that subscribers almost certainly missed. Three data catalysts are queued for Q4 2026 and the burn math is getting harder to ignore.
- GPCRStructure Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- GLUEMonte Rosa TherapeuticsReleaseMonte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
- FHTXFoghorn TherapeuticsReleaseFoghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
- FHTXFoghorn Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- FHTXFoghorn Therapeutics10-QQuarterly report
- FATEFate TherapeuticsSCHEDULE 13D/A13D amendment
- EXELExelixisSCHEDULE 13GPassive >5% holder (13G)
- EXELExelixisSCHEDULE 13D/A13D amendment
- EWTXEdgewise TherapeuticsReleaseEdgewise Therapeutics to Participate in Upcoming Investor Conference
- EVMNEvommuneReleaseEvommune to Present at Upcoming Investor Conferences
- DTILPrecision Biosciences8-KCurrent report: other events
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights→ BD updateSummary on the 8-K
- DFTXDefinium Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q and earnings release, filed after today's close, deliver the first human efficacy signal from DT402 (the R-MDMA "sleeper asset" in autism), confirm $1.05B cash with runway into 2030, and show commercial-preparedness spend accelerating — the thesis is transitioning from clinical to commercial, right on schedule.
- DFTXDefinium Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- CTNMContineum TherapeuticsReleaseQureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trialvia aggregator
- CRVSCorvus PharmaceuticalsReleaseCorvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
- CRVOCervoMedReleaseCervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
- CRVOCervoMed8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- CMPXCompass TherapeuticsReleaseCompass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- CMPXCompass Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE→ BD updateThe Q3 10-Q answers the question the October ESMO update left open: Compass is burning cash at an accelerating rate — $27M net loss in Q3 alone, $163M remaining, pre-commercialization spend continuing — while keeping the ATM untouched and pressing forward toward a BLA the FDA told them to hold.
- CMPXCompass Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- CMPSCOMPASS PathwaysReleaseCompass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression→ BD updateCompass just dropped the completed NDA for COMP360 — the filing that starts the CNPV voucher clock and sets the stage for a potential FDA decision as early as Q1 2027, months ahead of the standard review timeline.
- CLYMClimb BioSCHEDULE 13D/A13D amendment
- CHRSCoherus OncologyReleaseCoherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan→ BD updateSummary on the 8-K
- CHRSCoherus Oncology8-KCurrent report: results of operations · EX-99.1→ BD updateCoherus just restructured the company around esophageal cancer, cut headcount 30%, pushed the casdozo HCC readout to 1H 2027, and filed a going-concern 10-Q with $83.6M in cash — the thesis just changed shape, not just timing.
- CHRSCoherus Oncology10-QQuarterly report→ BD updateSummary on the 8-K
- CGTXCognition TherapeuticsReleaseCognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
- CGENCompugenReleaseCompugen Reports Third Quarter 2026 Results→ BD updateSummary on the 6-K
- CGENCompugen6-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateMAIA-ovarian is fully enrolled at n=62 and results are locked in for end of Q1 2027 — the owned binary is now a countdown, not a projection. Cash sits at $117.5M with runway into 2029 intact, and AstraZeneca's ARTEMIDE-01 Phase 2 delivered its first OS data in NSCLC.
- CGEMCullinan TherapeuticsReleaseCullinan Therapeutics to Participate in Upcoming Investor Conferences→ BD updateSummary on the 8-K
- CGEMCullinan Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateVelinotamig's expanded ACR dataset (n=12) shows 8/9 patients responding and 4/7 achieving complete renal responses in lupus nephritis — zero ICANS, no Grade 3+ CRS — giving the "second leg" of the Great Pivot a real data foundation ahead of the December CLN-978 mega-readout.
- CATXPerspective TherapeuticsReleasePerspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results→ BD updateSummary on the 8-K
- CATXPerspective Therapeutics8-KCurrent report: results of operations, other events · EX-99.1→ BD updateThe Q3 print quietly extends the runway to 2028, but buries a critical negative: BMS has terminated its nivolumab collaboration with VMT01 "due to economic factors," retiring the combo arm I've treated as a free call option since January.
- CATXPerspective Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- CAPRCapricor TherapeuticsReleaseCapricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
- CABACabaletta Bio8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateThe ACR data the thesis was waiting for just landed: 100% (6/6) DM patients holding IM-free responses at one year, zero IEC-HS across 71 patients — the exact safety signal that caused the class-wide panic is conspicuously absent from rese-cel's record, and the stock is responding.
- BDTXBlack Diamond TherapeuticsReleaseBlack Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC
- BCAXBicara TherapeuticsReleaseBicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- BCAXBicara Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateFORTIFI-HN01 has reached substantial enrollment — the gate to the mid-2027 interim analysis — while the fortified balance sheet ($442.3M, runway into 1H 2029) holds and burn accelerates as expected. The binary is now set.
- BCAXBicara Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- AVBPArriVent BioPharma8-KCurrent report: results of operations, officer / director change · EX-99.1 EXHIBIT 99.1
- AVBPArriVent BioPharma10-QQuarterly report
- AUTLAutolus TherapeuticsReleaseAUTOLUS THERAPEUTICS TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- ARTVArtiva Biotherapeutics8-K/ACurrent report (amended): exit / restructuring costs
- ARTVArtiva Biotherapeutics10-QQuarterly report
- APVOAptevo TherapeuticsReleaseAptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
- APVOAptevo Therapeutics8-KCurrent report: other events · EX-99.1
- ANTXAN2 TherapeuticsReleaseAN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights→ BD updateSummary on the 8-K
- ANTXAN2 Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateThe FDA IND for EBO-PV-201 has cleared — the single most important execution milestone the thesis was waiting for — and the Q3 10-Q reveals the ATM printed ~1.4M shares in Q3 alone, with $80.2M cash still intact and runway "into 2029."
- ANTXAN2 Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- ANNXAnnexonReleaseAnnexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones→ BD updateSummary on the 8-K
- ANNXAnnexon8-KCurrent report: results of operations · EX-99.1→ BD updateWith the ARCHER II DMC verdict weeks away, the Q3 filing reveals the strongest trial-execution metrics yet — 90% patient retention, all eligible patients past the 15-month mark, vision-loss events on track — while ANX1502 hit a formulation wall in CAD and Annexon quietly hired the former IZERVAY commercial lead to run the vonaprument franchise.
- ANNXAnnexon10-QQuarterly report→ BD updateSummary on the 8-K
- ALTAltimmuneReleaseAltimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder→ BD updateThe full RECLAIM dataset lands at AASLD as a late-breaker — cleaner than the July topline, with a new FIB-4 normalization signal and, more importantly, a December FDA End-of-Phase 2 meeting now formally on the calendar for the AUD Phase 3 program.
- ALLOAllogene TherapeuticsReleaseAllogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease→ BD update
- ALDXAldeyra Therapeutics8-KCurrent report: other events→ BD updateAldeyra just blew up the last piece of regulatory certainty in its pipeline — withdrawing the FDA-agreed trial design for ADX-2191 in PVRL and asking for the entire program to be reassigned to a different review division, with no guarantee it will be accepted.
- ADCTADC TherapeuticsReleaseADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates
- ADCTADC Therapeutics8-KCurrent report: results of operations · EX-99.1
- ADCTADC Therapeutics10-QQuarterly report
- ADAGAdageneReleaseAdagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer→ BD updateSummary on the 6-K
- ADAGAdagene6-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateAdagene just completed enrollment in its 60-patient randomized Phase 2 of muzastotug + pembrolizumab in MSS CRC — the trial that will set the Phase 3 dose — while simultaneously triggering Sanofi's final $8M equity tranche, completing a $25M non-dilutive strategic investment. The 1H 2027 readout clock is now officially running.
Sunday, November 85
- VIRVir BiotechnologyReleaseVir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta→ BD updateSummary on the 8-K of Nov 9, 2026
- VIRVir BiotechnologyReleaseVir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data→ BD updateSummary on the 8-K of Nov 9, 2026
- MLYSMineralys TherapeuticsReleaseMineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026→ BD updateTransform-HTN delivered: lorundrostat held −17.8 mmHg at week 48 and put 56% of patients below 130 mmHg, answering the durability question I flagged — but this is an open-label extension, not a randomized trial, and it doesn't move the needle on payer coverage or the AstraZeneca problem.
- CGEMCullinan TherapeuticsReleaseVelinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026→ BD updateSummary on the 8-K of Nov 9, 2026
- CABACabaletta BioReleaseCabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases→ BD updateSummary on the 8-K of Nov 9, 2026
Friday, November 647
- ZBIOZenas BioPharma8-KCurrent report: other events
- ZBIOZenas BioPharma424B5Prospectus supplement (offering)
- XNCRXencorSCHEDULE 13G/A13G amendment
- XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
- XENEXenon PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
- VRDNViridian TherapeuticsReleaseViridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
- VIRVir BiotechnologySCHEDULE 13D/A13D amendment
- UPBUpstream BioSCHEDULE 13G/A13G amendment
- TNGXTango TherapeuticsSCHEDULE 13G/A13G amendment
- TARAProtara TherapeuticsReleaseProtara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update→ BD updateSummary on the 8-K
- TARAProtara Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE DATED NOVEMBER 6, 2026, ISSUED BY THE REGISTRANT→ BD updateProtara just bought its own manufacturing facility for $8.75M, completed THRIVE-3 Phase 2b enrollment with interim data due by year-end, and confirmed ADVANCED-2 BCG-Unresponsive enrollment wraps Q4 — a dense catalyst stack into a name trading at ~41% below the post-ASCO close.
- TARAProtara Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- SLDBSolid BiosciencesSCHEDULE 13D/A13D amendment
- RNACCartesian TherapeuticsSCHEDULE 13G/A13G amendment
- REPLReplimune Group10-Q/AQuarterly report (amended)
- RAREUltragenyx PharmaceuticalReleaseUltragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Pvia aggregator
- QTTBQ32 BioSCHEDULE 13G/A13G amendment
- QTTBQ32 BioSCHEDULE 13G/A13G amendment
- QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
- QNRXQuoin Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- PTGXProtagonist Therapeutics10-QQuarterly report→ BD updateThe Q3 10-Q confirms the buyback is real ($5.8M executed, $294.2M remaining), drops ICONIC-ASCEND data for the first time (70% IGA 0/1 vs placebo, non-inferior to ustekinumab), and adds an NCCN Category 1 guideline win for MIMRYLO — while the ICOTYDE royalty line goes dark for a third straight quarter.
- PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
- PCVXVaxcyteSCHEDULE 13G/A13G amendment
- PCVXVaxcyteSCHEDULE 13G/A13G amendment
- OCGNOcugenDEFA14AProxy soliciting material
- OCGNOcugenDEFA14AProxy soliciting material
- NKTXNkartaReleaseNkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
- NKTXNkarta8-KCurrent report: Reg FD disclosure · EX-99.1
- KTTAPasithea TherapeuticsSCHEDULE 13G/A13G amendment
- INKTMiNK TherapeuticsReleaseMiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
- IMRXImmuneeringReleaseAtebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
- IMCRImmunocoreReleaseImmunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma→ BD updateSummary on the 8-K
- IMCRImmunocoreReleaseImmunocore reports third quarter financial results and provides a business update→ BD updateSummary on the 8-K
- IMCRImmunocore8-KCurrent report: results of operations · EX-99.1→ BD updateTEBE-AM's OS readout just slipped to Q2 2027 — the fourth milestone re-date on the most important catalyst in the company — while fresh SITC data show the KIMMTRAK + brenetafusp combination produced a 70% two-year OS rate in 17 first-line mUM patients, and Q3 revenue printed its first nominal year-over-year decline.
- IMCRImmunocore10-QQuarterly report→ BD updateSummary on the 8-K
- HURATuHURA Biosciences8-KCurrent report: debt / obligation
- HROWHarrowSCHEDULE 13G/A13G amendment
- HELPHelus Pharma6-KForeign issuer report · EX-99.1
- GUTSFractyl HealthReleaseFractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026
- GUTSFractyl Health8-KCurrent report: officer / director change
- GOSSGossamer BioSCHEDULE 13G/A13G amendment
- GOSSGossamer BioSCHEDULE 13GPassive >5% holder (13G)
- EYPTEyePointReleaseEyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
- ETONEton PharmaceuticalsSCHEDULE 13G/A13G amendment
- ENTXEntera BioReleaseEntera Announces Third Quarter 2026 Financial Results and Business Updates
- ENTXEntera Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- ENTXEntera Bio10-QQuarterly report
- DTILPrecision Biosciences8-KCurrent report: other events · EX-99.1
- DTILPrecision Biosciences424B5Prospectus supplement (offering)
- CTNMContineum TherapeuticsSCHEDULE 13G/A13G amendment
- CRVOCervoMed10-QQuarterly report→ BD update
- CMPXCompass TherapeuticsReleaseCompass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
- CGONCG OncologyReleaseCG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates→ BD updateSummary on the 8-K
- CGONCG Oncology8-KCurrent report: results of operations · EX-99.1→ BD updatePIVOT-006 Phase 3 topline is now "November 2026" — the Market Expander readout is weeks, not quarters, away — while ANI has escalated to the Delaware Supreme Court, introducing a wrinkle I called "mostly resolved." The stock surged 17.3% on today's Q3 print.
- CGONCG Oncology10-QQuarterly report→ BD updateSummary on the 8-K
- CATXPerspective TherapeuticsReleasePerspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026→ BD updateSummary on the 8-K
- CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1→ BD updateNANETS data reveals a sharper enrichment strategy for bamzireotide's Phase 3: SSTR2+ GEP-NET patients show 37–47% ORR and 75% PFS at 18 months, well above Lutathera's labeled benchmarks, with an End-of-Phase 2 FDA meeting now targeted for Q1 2027 — a meaningful step forward on the registration path I've been tracking all year.
- CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1→ BD updateSummary on the 8-K
- CADLCandel TherapeuticsReleaseCandel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- CABACabaletta BioSCHEDULE 13G/A13G amendment
- BCTXBriaCell TherapeuticsReleaseBriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026via aggregator
- ALLOAllogene Therapeutics10-QQuarterly report→ BD updateThe Q3 10-Q lands with three things subscribers need to know before Sunday: Cellectis just announced it's pivoting away from ex vivo CAR-T — the company that makes the TALEN scissors Allogene rents for cema-cel is now openly de-emphasizing the business — and Allogene is already hunting for alternative supply. Meanwhile, the ALLO-329 autoimmune data drops at ACR on November 9, the "autoimmune call option" I've been tracking all year. And Q3 burn on cema-cel alone jumped to $14M external, signaling manufacturing reactivation is real — and expensive.
- ALDXAldeyra TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- ACRVAcrivon TherapeuticsReleaseAcrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB→ BD updateSummary on the 8-K
- ACRVAcrivon Therapeutics8-KCurrent report: other events · EX-99.1→ BD updateAcrivon just bought a Phase 2-ready JAK1 inhibitor from Sweden's Aqilion AB, paying undisclosed cash with no future milestone or royalty obligations — and in the process formally declared immunology & inflammation a second strategic pillar alongside oncology. The AP3 platform's ability to characterize pathway activity without relying on genetic mutations may be even better suited to autoimmune disease than cancer.
Thursday, November 5193
- ZBIOZenas BioPharmaSCHEDULE 13G/A13G amendment
- ZBIOZenas BioPharmaReleaseZenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- ZBIOZenas BioPharma8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateNew OLE data shows 93% of patients remain flare-free at 12 months and obexelimab's B-cell brake can be released for vaccination — directly answering the reversibility and infection-risk questions — while the Q3 burn rate accelerates to ~$108M/quarter, SunStone inches closer, and the EMA clock starts ticking.
- ZBIOZenas BioPharma10-QQuarterly report→ BD updateSummary on the 8-K
- XERSXeris BiopharmaReleaseXeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights→ BD updateSummary on the 8-K
- XERSXeris Biopharma8-KCurrent report: results of operations · EX-99.1→ BD updateRecorlev just printed $71.5M in Q3 (+93% YoY), Xeris raised 2030 revenue guidance to >$1B, and the stock surged 25% on the earnings release — the cash engine is compounding faster than anyone (including me) modeled.
- XERSXeris Biopharma10-QQuarterly report→ BD updateSummary on the 8-K
- XENEXenon PharmaceuticalsSCHEDULE 13G/A13G amendment
- VYGRVoyager TherapeuticsReleaseVoyager Reports Third Quarter 2026 Financial and Operating Results→ BD updateSummary on the 8-K
- VYGRVoyager Therapeutics8-KCurrent report: acquisition / disposition · EX-99.1→ BD updateVoyager's Q3 print lands with $132.1M cash, a fully confirmed Q4 VY7523 PET readout, and VY1706 dosing on a "pending enrollment" clock — while the ATM is being worked below $3.50 and the stock now trades at a ~19% discount to cash.
- VYGRVoyager Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- VTVTvTv TherapeuticsReleasevTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- VTVTvTv Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updatevTv's Q3 print arrives with VTVT down ~28% from early October — the stock's slide predates tonight's release, and three of the most watched variables (ATM, cash runway, timeline) are mostly holding, though a CFO 10b5-1 plan and a quiet G42 timeline slip deserve attention.
- VTVTvTv Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- VSTMVerastemS-8Employee plan registration
- VSTMVerastemS-3ASRAutomatic shelf registration
- VSTMVerastemReleaseVerastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- VSTMVerastem8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- VSTMVerastem10-QQuarterly report
- VRCAVerrica PharmaceuticalsReleaseVerrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
- VORVor BiopharmaSCHEDULE 13G/A13G amendment
- VKTXViking TherapeuticsSCHEDULE 13G/A13G amendment
- VIRVir BiotechnologyReleaseVir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call
- VERAVera TherapeuticsReleaseVera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- VERAVera Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateTRUTAKNA's first revenue quarter clears $10M on ~700 patient start forms, the ORIGIN 3 data lands in the NEJM, the sBLA is filed, and PIONEER flashes its first signal — yet VERA trades 29% below the December offering price.
- VERAVera Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- TYRATyra BiosciencesReleaseTyra Biosciences to Participate in Upcoming Investor Conferences
- TVTXTravere TherapeuticsSCHEDULE 13G/A13G amendment
- TTRXTurn TherapeuticsReleaseTurn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program
- TSHATaysha Gene TherapiesReleaseTaysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
- TLSATiziana Life SciencesReleaseTiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED NOVEMBER 5, 2026
- TENXTenax TherapeuticsReleaseTenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- TENXTenax Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q revealed a tighter LEVEL-2 enrichment design (+34 m in qualifying patients, 95% CI 15–53), confirmed the Type C meeting is granted, disclosed a securities class-action lawsuit, and showed the August 2024 warrant tranche expired worthless — four developments that collectively update the post-LEVEL bear and watch-list picture.
- TENXTenax Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- TECXTectonic TherapeuticReleaseReported favorable safety, tolerability and pharmacokinetic (“PK”) results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adult volunteers; FDA granted TX2100→ BD updateSummary on the 8-K
- TECXTectonic Therapeutic8-KCurrent report: acquisition / disposition · EX-99.1→ BD updateAPEX is now inside an 8-week window (end of January 2027), ALPINE dosed its first patient, the ATM accelerated to $22.3M in Q3 alone, and — buried in the 10-Q risk factors — Tectonic itself flags that AZD5462's LUMINARA data "may have affected investor perception of relaxin product candidates," which may help explain the stock's -16.8% slide since the September update.
- TECXTectonic Therapeutic10-QQuarterly report→ BD updateSummary on the 8-K
- STOKStoke TherapeuticsSCHEDULE 13G/A13G amendment
- SRPTSarepta TherapeuticsReleaseSarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments→ BD updateSummary on the 8-K
- SRPTSarepta Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 2026 earnings land with the PMO sNDA PDUFA date finally disclosed (February 28, 2027), MAD data for SRP-1003 and SRP-1001 locked in for Q4 2026 with Phase 3 prep already underway, and the balance sheet growing to ~$999M — but a new $62M Catalent take-or-pay charge and a 7.5% session drop heading into the print keep the tension alive.
- SRPTSarepta Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- SLDBSolid BiosciencesReleaseSolid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conferencevia aggregator
- SCYXScynexisS-3Shelf registration→ BD updateSummary on the 10-Q
- SCYXScynexisReleaseSCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 10-Q
- SCYXScynexis10-QQuarterly report→ BD updateThe Phase 1 SCY-770 gating study is done, the Phase 2 clock is ticking, and SCYX just hired a nephrologist to run R&D — but the stock is down 14% on the day, and the market is reading the S-3 shelf renewal as a capital-raise signal.
- SANASana BiotechnologySCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- SANASana BiotechnologyReleaseSana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates→ BD updateSummary on the 8-K
- SANASana Biotechnology8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 delivered a GAAP profit (a $63M non-cash accounting gain, not a business transformation), but underneath the headlines: SG293 first-in-human data slipped to 1Q 2027, Mayo passed on its $25M second tranche, and the going-concern flag persists on $121.7M cash — the thesis is tracking but the runway is tighter and the binary catalyst window just moved.
- SANASana Biotechnology10-QQuarterly report→ BD updateSummary on the 8-K
- SABSSAB BiotherapeuticsReleaseSAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights→ BD updateSummary on the 10-Q
- SABSSAB Biotherapeutics10-QQuarterly report→ BD updateSAFEGUARD's adult and adolescent cohorts just closed for screening — the enrollment milestone I told you to watch for. The 10-Q also surfaces a quiet internal signal: management's "probability of survival" assumption jumped from 57.5% to 70.0% in a single quarter.
- RVMDRevolution MedicinesSCHEDULE 13G/A13G amendment
- RNACCartesian TherapeuticsReleaseCartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- RNACCartesian Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings confirm the AURORA 1Q27 readout and mid-2027 BLA are on track, but quarterly burn has accelerated to ~$98M annualized and the WestGene in vivo trial hasn't launched yet — with the K2HV covenant clock now five months away, the execution margin is tighter than it looked in August.
- RNACCartesian Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- QNRXQuoin PharmaceuticalsReleaseQuoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- QNRXQuoin Pharmaceuticals10-QQuarterly report
- PTGXProtagonist TherapeuticsReleaseProtagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Updatevia aggregator→ BD updateSummary on the 8-K
- PTGXProtagonist Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateQ3 2026 earnings land after the close: ICOTYDE royalties go undisclosed for a second consecutive full commercial quarter, PN-477sc delivers positive Phase 1 SAD data prompting a strategic pivot to the oral program, and cash prints at $834.6M — confirming the Q4 timing gap I flagged in September.
- PMNProMIS NeurosciencesReleaseProMIS Neurosciences to Participate in Upcoming Conferences in November
- PHIOPhio PharmaceuticalsReleasePhio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation→ BD updateSummary on the 8-K
- PHIOPhio Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateThe Q3 10-Q lands a going-concern flag and a Nasdaq minimum-bid-price warning (21 of 30 consecutive days already below $1.00) while cash falls to $10.6M — the death-by-a-thousand-warrants thesis just got a formal auditor co-sign, with an FDA response due by end of November as the only potential escape valve.
- PHIOPhio Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- PCSAProcessa PharmaceuticalsDEFA14AProxy soliciting material
- PCSAProcessa PharmaceuticalsDEFA14AProxy soliciting material
- PCSAProcessa Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates→ BD updateSummary on the 8-K
- NTLAIntellia Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings landed this morning with MAGNITUDE-2 enrollment complete (exceeding its target), a new CMO aboard, and a $127.5M net loss that includes a $10.4M non-cash investment writedown — the market sold the print −9.8%, likely misreading the headline; here's what actually changed and what didn't.
- NTLAIntellia Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- NRXPNRX PharmaceuticalsDEFA14AProxy soliciting material
- NRXPNRX PharmaceuticalsDEF 14AProxy statement
- NRIXNurix TherapeuticsSCHEDULE 13G/A13G amendment
- NRIXNurix TherapeuticsReleaseNurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
- NKTXNkartaReleaseNkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
- NKTXNkarta8-KCurrent report: results of operations · EX-99.1
- NKTXNkarta10-QQuarterly report
- NBPNovaBridge BiosciencesSCHEDULE 13D/A13D amendment
- NAMSNewAmsterdam PharmaSCHEDULE 13G/A13G amendment
- MESOMesoblastReleaseUse Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinarvia aggregator
- MBXMBX BiosciencesSCHEDULE 13G/A13G amendment
- LRMRLarimar TherapeuticsReleaseLarimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
- LGVNLongeveronSCHEDULE 13G/A13G amendment
- LGVNLongeveron8-KCurrent report: officer / director change
- LENZLENZ TherapeuticsSCHEDULE 13G/A13G amendment
- LEGNLegend BiotechSCHEDULE 13G/A13G amendment
- LCTXLineage Cell TherapeuticsReleaseLineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
- LBRXLB PharmaceuticalsReleaseLB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- LBRXLB Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateLBRX's Q3 10-Q checks every box on my watch list: $403.8M in cash (at the top of my estimate), NOVA-2 enrollment "progressing strongly" with 1H 2027 readout intact, and two new senior hires filling the leadership gaps that were the clearest near-term bear flags.
- LBRXLB Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- KZIAKazia TherapeuticsReleaseKazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
- KYTXKyverna TherapeuticsReleaseKyverna Therapeutics to Present at the Jefferies London Healthcare Conference
- KROSKeros TherapeuticsReleaseKeros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results→ BD update
- KROSKeros Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1→ BD update
- KROSKeros Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD update
- KROSKeros Therapeutics10-QQuarterly report→ BD update
- KAPAKairos PharmaReleaseKairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
- KAPAKairos Pharma8-KCurrent report: other events · EX-99.1
- JANXJanux TherapeuticsReleaseJanux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights→ BD updateSummary on the 8-K
- JANXJanux Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateFour days before Janux presents the first clinical data from the ARM platform (JANX011), the Q3 release drops a new mechanism disclosure: the drug selectively engages a specific T cell subset (TRBV6-expressing) rather than broad CD3+ activation — a detail that completely reframes what readers should be watching for on November 9.
- JANXJanux Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- IRONDisc MedicineReleasePivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints Bitopertin NDA resubmission planned by end of 2026, with an FDA d
- IRONDisc Medicine8-KCurrent report: results of operations · EX-99.1
- IRONDisc Medicine424B5Prospectus supplement (offering)
- IRONDisc Medicine10-QQuarterly report
- IRDOpus GeneticsReleaseOpus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
- INMBInmune BioReleaseINmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update→ BD updateSummary on the 10-Q
- INMBInmune Bio10-QQuarterly report→ BD updateQ3 reveals $16.3M cash and a drained Australian rebate well — the non-dilutive buffer that bought time all year is gone — while management guides runway through Q3 2027 and quietly pivots XPro toward a quantum-computing-assisted rare-disease search.
- INABIN8bioReleaseIN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights→ BD updateSummary on the 8-K
- INABIN8bio8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 puts $14.0M cash against an April 2027 wall, but the hire of a gamma-delta TCE pioneer as SVP of R&D and INB-619's debut in Nature Reviews Drug Discovery signal a company accelerating toward the year-end animal data that could unlock the $20.1M PIPE second tranche — if the listing holds.
- INABIN8bio10-QQuarterly report→ BD updateSummary on the 8-K
- IMUXImmunic8-KCurrent report: Reg FD disclosure · EX-99.1
- GRCEGrace TherapeuticsReleaseGrace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
- GPCRStructure TherapeuticsSCHEDULE 13G/A13G amendment
- GLUEMonte Rosa TherapeuticsReleaseMonte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
- GLUEMonte Rosa Therapeutics8-KCurrent report: results of operations · EX-99.1
- GLUEMonte Rosa Therapeutics10-QQuarterly report
- GHRSGH ResearchSCHEDULE 13G/A13G amendment
- GANXGain TherapeuticsReleaseGain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
- FBIOFortress BiotechReleaseJourney Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
- FATEFate TherapeuticsS-3Shelf registration→ BD updateSummary on the 8-K
- FATEFate TherapeuticsReleaseFate Therapeutics Reports Third Quarter 2026 Financial Results And Business Updates→ BD updateSummary on the 8-K
- FATEFate Therapeutics8-KCurrent report: material agreement, agreement terminated→ BD updateFate's Q3 print confirms the raise I said was inevitable has begun — a fresh $100M ATM with Leerink is live, cash sits at $139.1M (plus a $15M CIRM grant), and the runway guidance nudges to mid-2028; now we know exactly what the dilution trap looks like.
- FATEFate Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateSummary on the 8-K
- FATEFate Therapeutics424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- FATEFate Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- EYPTEyePointReleaseEyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
- EWTXEdgewise TherapeuticsSCHEDULE 13G/A13G amendment→ BD update
- EWTXEdgewise TherapeuticsReleaseEdgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring→ BD update
- EVMNEvommuneReleaseEvommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
- EVMNEvommune8-KCurrent report: Reg FD disclosure · EX-99.1
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability→ BD updateSummary on the 8-K
- ETONEton Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateEton printed a blowout Q3 — $57.9M revenue, 49% Adjusted EBITDA margin, guidance raised to >$175M — but the ET-700 pilot data delivered a split verdict: excellent tolerability (1/12 AEs vs. 8/12 for GALZIN), underwhelming copper blockade (12% reduction vs. 46%), pushing the program back into reformulation and delaying the >$100M peak-sales catalyst into 2027 or beyond.
- ETONEton Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO ET-700→ BD updateSummary on the 8-K
- ETONEton Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- ELVNEnliven TherapeuticsReleaseEnliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
- ELVNEnliven Therapeutics8-KCurrent report: results of operations · EX-99.1
- ELVNEnliven Therapeutics10-QQuarterly report
- ELTXElicio TherapeuticsReleaseElicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- ELTXElicio Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateElicio's Q3 print extends the cash runway to Q2 2027 — removing the imminent extinction risk flagged in October — while the Q4 2026 Phase 1 combination trial with daraxonrasib remains on track, but going-concern language persists and no partner has materialized.
- ELTXElicio Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- DYNDyne TherapeuticsReleaseDyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights→ BD updateSummary on the 8-K
- DYNDyne Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 burn hit $193.6M as launch prep spending surges 65% YoY; cash sits at $1.134B into Q2 2028, but the BIOSECURE CDMO injunction and new pharma tariff risk add nuance to the supply chain picture heading into the January 21 PDUFA.
- DYNDyne Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- DTILPrecision BiosciencesReleasePrecision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study→ BD updateSummary on the 8-K
- DTILPrecision BiosciencesReleasePrecision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants→ BD updateSummary on the 8-K
- DTILPrecision BiosciencesReleasePrecision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure→ BD updateSummary on the 8-K
- DTILPrecision BiosciencesFWPFree writing prospectus (offering terms)→ BD updateSummary on the 8-K
- DTILPrecision Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateToday was the day I said to wait for: PBGENE-HBV's AASLD data beat the bar I set, the first DMD patient cleared the 8-week safety window the field was watching, and a $125M offering at $7.75 — backed by named institutional buyers — just retired the dilution trap I called the most dangerous item in the bear case.
- DFTXDefinium TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CTNMContineum TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- CTMXCytomX TherapeuticsReleaseCytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- CTMXCytomX Therapeutics8-KCurrent report: results of operations · EX-99.1 CYTOMX Q3 2026 EARNINGS RELEASE_DRAFT_POST_AC_FOR APPROVAL→ BD updateQ3 earnings confirm the dose-selection data readout slips to January 2027, BMS's termination is now on the books, and the stock has cratered 37% since the August Fast Track update — but $348M in cash and an expanding indication footprint say the thesis isn't broken, just delayed.
- CTMXCytomX Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- CRVSCorvus PharmaceuticalsReleaseCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- CRVSCorvus Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE→ BD updateCorvus's Q3 2026 update delivered the first real clinical data since my original deep dive — ALPS Phase 2 initial results show soquelitinib's immune-rebalancing mechanism working in a genetically-confirmed rare disease, while the 2027 catalyst calendar is now tighter and better-defined than ever.
- CRVSCorvus Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- CRBUCaribou BiosciencesReleaseCaribou Biosciences Reports Third Quarter 2026 Financial Results
- CRBUCaribou Biosciences8-KCurrent report: results of operations · EX-99.1
- CRBUCaribou Biosciences10-QQuarterly report
- COGTCogent BiosciencesReleaseCogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- COGTCogent Biosciences8-KCurrent report: results of operations · EX-99.1→ BD updateWith the GIST PDUFA 25 days out, Cogent's Q3 print shows a commercial build burning fast — G&A tripled to $42.1M in a single quarter — but $791M in cash, $108.5M in locked-in CMO commitments, and a first clinical look at the avapritinib-switch data at ASH keep the thesis intact heading into the most consequential month in the company's history.
- COGTCogent Biosciences10-QQuarterly report→ BD updateSummary on the 8-K
- CLYMClimb BioSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- CLYMClimb BioS-3ASRAutomatic shelf registration→ BD updateSummary on the 8-K
- CLYMClimb BioReleaseClimb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates→ BD updateSummary on the 8-K
- CLYMClimb Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateQ3 earnings surface three under-the-radar thesis updates: Fidelity emerges at 15% ownership, the ATM drew its first $10.1M at $10.00/share in October, and the Delaware summary-judgment hearing on the $157.5M Acelyrin milestone fight has now been held — with a ruling pending.
- CLYMClimb Bio10-QQuarterly report→ BD updateSummary on the 8-K
- CLDXCelldex TherapeuticsS-3ASRAutomatic shelf registration
- CLDXCelldex TherapeuticsReleaseCelldex Reports Third Quarter Financial Results and Provides Corporate Update
- CLDXCelldex Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE
- CLDXCelldex Therapeutics10-QQuarterly report
- CGTXCognition TherapeuticsReleaseCognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update→ BD updateSummary on the 8-K
- CGTXCognition Therapeutics8-KCurrent report: results of operations, listing notice · EX-99.1 EXHIBIT 99.1→ BD updateNasdaq sent the deficiency letter — CGTX officially has until May 3, 2027 to get back above $1.00. The Q3 print shows the balance sheet is holding up better than feared, but the listing clock is now ticking in writing.
- CGTXCognition Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- CCCCC4 TherapeuticsReleaseC4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- CCCCC4 Therapeutics8-KCurrent report: results of operations · EX-99.1
- CCCCC4 Therapeutics10-QQuarterly report
- CATXPerspective TherapeuticsReleasePerspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
- CAMPCamp4 TherapeuticsSCHEDULE 13G/A13G amendment
- CAMPCamp4 Therapeutics8-KCurrent report · EX-99.1
- CAMPCamp4 Therapeutics10-QQuarterly report
- CABACabaletta BioReleaseCabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- CABACabaletta Bio8-KCurrent report: results of operations · EX-99.1→ BD updateCabaletta's Q3 earnings reveal a 3Q enrollment slowdown in the myositis registrational cohort — blamed on Novartis/BMS competitor safety events — pushing the BLA submission to 1Q28, while $299.4M in cash buys runway to that date and ACR drops one-year DM durability data this Sunday.
- CABACabaletta Bio10-QQuarterly report→ BD updateSummary on the 8-K
- BLTEBelite BioReleaseBelite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
- BIOABioAge LabsReleaseBioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates→ BD updateSummary on the 8-K
- BIOABioAge Labs8-KCurrent report: results of operations · EX-99.1→ BD updateQUELL-CV topline is now locked to Q4 2026 — the binary is weeks away — but a new manufacturing risk just appeared in the fine print: BioAge's CDMO WuXi AppTec was placed on the Pentagon's Chinese Military Company list in June 2026, adding supply-chain uncertainty to a thesis that was otherwise tracking cleanly into the readout.
- BIOABioAge Labs10-QQuarterly report→ BD updateSummary on the 8-K
- BBOTBridgeBio Oncology Therapeutics8-KCurrent report: officer / director change
- AVBPArriVent BioPharmaSCHEDULE 13G/A13G amendment
- APVOAptevo TherapeuticsReleaseAptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
- APVOAptevo Therapeutics8-KCurrent report: other events · EX-99.1
- ANNXAnnexonSCHEDULE 13G/A13G amendment
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- AMLXAmylyx Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings bring the two things the thesis needed most: Amylyx has signed a definitive manufacturing deal with Bachem Americas and a binding term sheet with Polypeptide Group AG (with a $30M upfront capacity reservation), closing the CMC risk I'd been flagging as the last major overhang — and the stock has quietly given back 30% of its post-LUCIDITY gains, setting up an interesting entry point ahead of the ObesityWeek data presentation on November 15.
- AMLXAmylyx Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- ALTAltimmuneReleaseAltimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
- ALTAltimmuneReleaseAltimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
- ALMSAlumisSCHEDULE 13G/A13G amendment
- ALLOAllogene TherapeuticsReleaseAllogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
- ALLOAllogene Therapeutics8-KCurrent report: results of operations · EX-99.1
- ALDXAldeyra Therapeutics10-QQuarterly report→ BD update
- AKBAAkebia TherapeuticsReleaseAkebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights→ BD updateSummary on the 8-K
- AKBAAkebia TherapeuticsReleaseAkebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin→ BD updateSummary on the 8-K
- AKBAAkebia Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateVOCAL hit its non-inferiority endpoint against ESA, completing the clinical evidence arc — but Vafseo's Q3 revenues collapsed to $14.8M on TDAPA inventory destocking even as patients grew to 11,500, exposing the full brutality of the post-TDAPA price reset that starts January 1.
- AKBAAkebia Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- AGIOAgios PharmaceuticalsReleaseAgios Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- AGIOAgios Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateAGIO dropped ~10% on Q3 results that actually showed record revenue of $55.4M — the thalassemia launch is accelerating faster than the bear case allowed, with 75% six-month retention, but the market appears to be pricing the REMS/February-label uncertainty and a new R&D headcount cut that acknowledges the cost base problem.
- AGIOAgios Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- ACRSAclaris TherapeuticsReleaseAclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
- ACRSAclaris Therapeutics8-KCurrent report: results of operations · EX-99.1
- ACRSAclaris Therapeutics10-QQuarterly report
- ACETAdicet BioReleaseAdicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates→ BD updateSummary on the 8-K
- ACETAdicet Bio8-KCurrent report: results of operations · EX-99.1→ BD updateAdicet's Q3 10-Q — filed after the close — contains a formal going-concern disclosure and a $100.9M cash balance against ~$79M annualized burn, with the pivotal readout not until 2029. The raise is no longer a risk; it's a schedule.
- ACETAdicet Bio10-QQuarterly report→ BD updateSummary on the 8-K
- ABOSAcumen Pharmaceuticals8-KCurrent report: agreement terminated, exit / restructuring costs
Wednesday, November 4144
- XNCRXencorReleaseXencor Reports Third Quarter 2026 Financial Results
- XNCRXencor8-KCurrent report: results of operations · EX-99.1
- XNCRXencor10-QQuarterly report
- XFORX4 PharmaceuticalsReleaseX4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 10-Q
- XFORX4 Pharmaceuticals10-QQuarterly report→ BD updateThe Q3 10-Q finally discloses the K2 covenant structure — a 75%-of-debt cash lock starting Oct 1, 2027 that compresses usable runway ahead of the H1 2028 4WARD readout — while 4STEPS emerges as a new clinical program and WHIM sales tick up for the first time in three quarters.
- VRDNViridian TherapeuticsReleaseViridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress→ BD updateSummary on the 8-K
- VRDNViridian Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateLumvoa's first real revenue quarter prints $24.7M — ahead of what a mid-quarter launch should deliver — and the stock surged 15.5% on the day; the J-code, the Q4 pipeline catalysts, and the royalty math all need a fresh read.
- VRDNViridian Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- VIRVir BiotechnologyReleaseVir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- VIRVir Biotechnology8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings land with ECLIPSE 1 now explicitly "this quarter," VIR-5500 earns FDA Fast Track and proof-of-concept status, and the VIR-5818 HER2 data timeline quietly slips on FDA Project Optimus feedback — the platform-generalization test just got delayed.
- VIRVir Biotechnology10-QQuarterly report→ BD updateSummary on the 8-K
- UNCYUnicycive TherapeuticsReleaseUnicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
- TNGXTango TherapeuticsReleaseTango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
- STROSutro BiopharmaReleaseSutro Biopharma to Participate in Upcoming Investor Conferencesvia aggregator
- SNDXSyndax PharmaceuticalsReleaseSyndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026via aggregator
- SNDXSyndax PharmaceuticalsReleaseSyndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026via aggregator
- SMMTSummit TherapeuticsReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026→ BD updateSummary on the 8-K
- SMMTSummit Therapeutics8-KCurrent report: results of operations, charter / bylaws / fiscal year, shareholder vote · EX-99.1→ BD updateSummary on the 8-K
- SMMTSummit Therapeutics8-KCurrent report: other events→ BD updateWith the authorized-share vote cleared today and the PDUFA 10 days out, Summit enters its most consequential window yet — a fortified balance sheet, imminent HARMONi-3 squamous data, and a binary FDA decision all stacking into the same fortnight.
- SMMTSummit Therapeutics424B7Prospectus supplement→ BD updateSummary on the 8-K
- SMMTSummit Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- SLSSELLAS Life Sciences GroupReleaseSELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026→ BD updateWith the REGAL binary imminent, SELLAS's Plan B just got a lot more real: SLS009 Phase 2 data headed to ASH shows 54–57% ORR in venetoclax-failed, high-risk AML subgroups where historical survival is ~2.5 months — and the safety profile is clean.
- SLDBSolid BiosciencesReleaseSolid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
- SLDBSolid Biosciences10-QQuarterly report
- SEPNSepterna8-KCurrent report: Reg FD disclosure · EX-99.1
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
- RVMDRevolution MedicinesReleaseRevolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress→ BD updateSummary on the 8-K
- RVMDRevolution Medicines8-KCurrent report: results of operations · EX-99.1→ BD update$197.6M in RASONQUE net revenue on five weeks of sales, >5,000 patients, >90% covered lives reimbursed — the first commercial print just answered the question the whole Watch List thesis was waiting on.
- RVMDRevolution Medicines10-QQuarterly report→ BD updateSummary on the 8-K
- RLMDRelmada TherapeuticsReleaseRelmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in Londonvia aggregator
- RLAYRelay TherapeuticsReleaseRelay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates→ BD updateSummary on the 8-K
- RLAYRelay Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateRelay's Q3 print — released after the close — brings three thesis-movers: ReDiscover-2 enrollment tracking ~1 year ahead of benchmark (mid-2027 completion), updated ReInspire vascular anomaly data locked in for an ASH oral on December 14 with a same-day regulatory call, and a commercial hire (Shannon Campbell, ex-Merus CCO) signaling Relay is treating launch as a planning reality. The December 14 ASH readout is now the clearest near-term de-risking event in the story.
- RLAYRelay Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- RCUSArcus BiosciencesReleaseArcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pi...→ BD updateSummary on the 8-K
- RCUSArcus Biosciences8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings confirm the fortress balance sheet now reaches into 2029 post-offering, Arcus named a fifth bispecific partner (Pfizer's tivunatamig), and the PRISM-1 interim analysis in pancreatic cancer is now expected this quarter — a binary catalyst I flagged as a "synthetic-control-arm coin flip" that has been quietly approaching.
- RCUSArcus Biosciences10-QQuarterly report→ BD updateSummary on the 8-K
- RAREUltragenyx Pharmaceutical10-QQuarterly report→ BD updateThe Q3 10-Q puts real numbers on the post-Aspire thesis for the first time: a $43M operating cash draw, ~$750M of pro-forma liquidity once both PRV sales close, and zero gene therapy revenue yet — the launch ramp that determines whether the 2027 profitability target is real is now the only story left to watch.
- RAPPRapport Therapeutics8-KCurrent report: results of operations · EX-99.1
- RAPPRapport Therapeutics10-QQuarterly report
- QUREuniQureReleaseuniQure Announces Third Quarter 2026 Financial Results and Provides Company Updatevia aggregator
- QUREuniQure8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- QUREuniQure10-QQuarterly report
- QTTBQ32 BioReleaseQ32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- QTTBQ32 Bio8-KCurrent report: results of operations · EX-99.1
- QTTBQ32 Bio10-QQuarterly report
- QNRXQuoin PharmaceuticalsEFFECTRegistration effective→ BD updateSummary on the 8-K
- QNRXQuoin Pharmaceuticals8-KCurrent report: material agreement→ BD updateQuoin filed a new $11M at-the-market equity facility with Leerink after the close — just 10 weeks after closing a $30.8M PIPE — adding a continuous dilution spigot to a stock already down 44% from its September high and raising the question of why fresh capital is needed this soon.
- QNRXQuoin Pharmaceuticals424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- QNRXQuoin Pharmaceuticals424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- PMVPPMV PharmaceuticalsReleasePivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
- PCVXVaxcyteReleaseVaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- PCVXVaxcyte8-KCurrent report: results of operations · EX-99.1→ BD updateAfter the October OPUS-1 win and $1.1B raise, the Q3 10-Q restores the fortress balance sheet to ~$3.4B pro forma, cuts near-term manufacturing commitments, and quietly escalates the ACIP risk I've been flagging since day one — now acknowledged in Vaxcyte's own risk factors for the first time.
- PCVXVaxcyte10-QQuarterly report→ BD updateSummary on the 8-K
- PCSAProcessa PharmaceuticalsReleaseProcessa Pharmaceuticals Announces Key Leadership Appointments
- PCSAProcessa Pharmaceuticals8-KCurrent report: officer / director change, other events · EX-99.1 EXHIBIT 99.1
- ONCYOncolytics BiotechReleaseTranslational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
- ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
- OLMAOlema PharmaceuticalsReleaseOlema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium
- OKUROnKure TherapeuticsReleaseOnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights→ BD updateSummary on the 8-K
- OKUROnKure Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q answers the three questions I told you to track: the ATM is still clean (zero shares sold), cash is $163.3M (~$3.27/share, still above the stock price), and PIKture-01 is still missing from every filing with SABCS seven weeks away. Two China-based CMOs are named for the first time, adding a supply-chain risk I could only flag as theoretical before.
- OKUROnKure Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- OCGNOcugenReleaseOcugen Provides Business Update with Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- OCGNOcugen8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateOcugen's Q3 2026 earnings landed with a nearly flat net loss of $3.6M — dramatically better than the year-ago $20M — driven by a $16.6M derivative liability mark-down as the stock slid from convertible pricing levels; the December 22 authorized-share vote is confirmed; and the investor deck breaks out new OCU400 Phase 1/2 data showing 71.4% of the 7-patient ITT cohort projected to clear the Phase 3 response bar.
- OCGNOcugen10-QQuarterly report→ BD updateSummary on the 8-K
- NVCTNuvectis PharmaReleaseNuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlightsvia aggregator→ BD updateSummary on the 8-K
- NVCTNuvectis Pharma8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateThe Q3 report brings the first confirmation that FDA discussions on a U.S. ciprocopan path are "well underway," but the NXP900 Phase 1b combination update has quietly slipped to 1H 2027 — and the ATM's $37M single-fund placement finally starts to answer the institutional-sponsorship question.
- NVCTNuvectis Pharma10-QQuarterly report→ BD updateSummary on the 8-K
- NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
- NAMSNewAmsterdam PharmaReleaseNewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results→ BD updateSummary on the 8-K
- NAMSNewAmsterdam Pharma8-KCurrent report · EX-99.1→ BD updateWith the PREVAIL interim event count on track for Q4 2026 and a DSMB recommendation landing in Q1 2027, the binary I've been tracking is now weeks away — and today's Q3 update confirms $643.1M in cash, a new Phase 2b Alzheimer's trial (SPINOZA), and a RUBENS readout before year-end.
- NAMSNewAmsterdam Pharma10-QQuarterly report→ BD updateSummary on the 8-K
- MLYSMineralys TherapeuticsReleaseMineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- MLYSMineralys Therapeutics8-KCurrent report: results of operations, officer / director change · EX-99.1→ BD updateQ3 earnings confirm the launch-cost ramp is steeper than prior quarters ($37.4M G&A vs. $9.7M a year ago), the Tanabe IP transfer is finally closed, RA Capital's board representative just resigned, and a 100%-tariff risk on drug imports is disclosed for the first time—all with 7 weeks to the PDUFA.
- MLYSMineralys Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- MLTXMoonLake ImmunotherapeuticsReleaseMoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update→ BD updateSummary on the 8-K
- MLTXMoonLake Immunotherapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateMoonLake submitted the HS BLA on September 30 and will hear on acceptance by end of November — the thesis-defining unlock — but the Q3 10-Q reveals the Tranche 4 $50M quietly lapsed into the discretionary Tranche 6 and a $17M MHKDG milestone is already accrued, tightening the balance sheet further than the "$498.5M / mid-2028 runway" headline implies.
- MLTXMoonLake Immunotherapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- MDNAFMedicenna TherapeuticsReleaseMedicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders
- MBRXMoleculin BiotechReleaseMoleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
- MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- LXEOLexeo TherapeuticsEFFECTRegistration effective
- LRMRLarimar TherapeuticsReleaseLarimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- LENZLENZ TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
- LEGNLegend BiotechReleaseLegend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
- LEGNLegend Biotech6-KForeign issuer report · EX-99.1 PRESS RELEASE
- KURAKura OncologyReleaseKura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
- IRONDisc MedicineReleaseTwo oral presentations featuring additional data from RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis (MF) and RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera (
- INSMInsmedReleaseInsmed to Present at November and December 2026 Investor Conferences
- IMRXImmuneeringReleaseImmuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
- IMRXImmuneeringReleaseImmuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
- IMNMImmunomeReleaseImmunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026via aggregator→ BD updateIM-1021 delivers a 53% ORR (64% in DLBCL) across all dose levels in heavily pretreated B-NHL patients — the first human proof that the HC74 TOP1i payload engine works, the exact catalyst I said could convert optionality into an asset.
- IMMXImmix BiopharmaReleaseImmix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
- IDYAIDEAYA BiosciencesReleaseIDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
- IBRXImmunityBioReleaseImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
- HURATuHURA BiosciencesReleaseTuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
- HRMYHarmony BiosciencesReleaseHarmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting→ BD updateSummary on the 8-K
- HRMYHarmony Biosciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateHarmony's Q3 earnings and BP-205 MAD data land on the same day — the first repeated-dose safety look at its orexin agonist clears the critical liver/cardiac bar, while WAKIX hits $269M (+12%) and a new legal calendar accelerates the patent-cliff timeline into early 2027.
- HRMYHarmony Biosciences10-QQuarterly report→ BD updateSummary on the 8-K
- GPCRStructure TherapeuticsReleaseStructure Therapeutics to Participate in the Jefferies Global Healthcare Conference
- GNLXGeneluxSCHEDULE 13G/A13G amendment
- GERNGeronReleaseGeron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights→ BD updateSummary on the 8-K
- GERNGeronReleaseGeron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026→ BD updateSummary on the 8-K
- GERNGeron8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 2026 delivered GERN's first clean operating profit ($5.8M) post-IMpactMF collapse, cash grew sequentially to $339M, and demand accelerated 10% QoQ to 1,700 accounts — but the securities class action survived a motion to dismiss and is now in discovery, adding a new and unpriced tail risk to the already-levered balance sheet.
- GERNGeron10-QQuarterly report→ BD updateSummary on the 8-K
- FBRXForte BiosciencesSCHEDULE 13G/A13G amendment
- EYPTEyePointSCHEDULE 13G/A13G amendment
- EWTXEdgewise TherapeuticsReleaseEdgewise Therapeutics Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- EWTXEdgewise Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateEdgewise's Q3 print confirmed a better-than-estimated tax bill ($155M vs. ~$226M feared), leaving $1.74B in cash — but GRAND CANYON failed on November 3, wiping the $100–200M Becker milestone off the table, while EDG-15400 quietly dosed its first HFpEF patient, closing the Phase 1 disclosure gap I flagged in the original writeup.
- EWTXEdgewise Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- EVMNEvommuneReleaseEvommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals→ BD updateSummary on the 8-K
- EVMNEvommuneReleaseEvommune Announces $30 Million Private Placement→ BD updateSummary on the 8-K
- EVMNEvommune8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1→ BD updateEvommune just reloaded the pipeline with a licensed VAV1 molecular glue degrader (EVO570) showing ~20× greater preclinical potency than Novartis's MRT-6160, backed by a $30M PIPE at current prices from OrbiMed, Adage, and Balyasny — a meaningful signal that institutional money is re-engaging the story after two EVO756 failures.
- EVMNEvommune424B3Prospectus (resale / update)→ BD updateSummary on the 8-K
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
- ERASErascaReleaseTango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
- ENTAEnanta PharmaceuticalsReleaseEnanta Pharmaceuticals to Participate in Upcoming Investor Conferences
- ELTXElicio TherapeuticsReleaseElicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- CRVSCorvus PharmaceuticalsReleaseCorvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hemato
- CRBUCaribou BiosciencesReleaseCaribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
- CMPSCOMPASS PathwaysReleaseCompass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
- CLYMClimb BioReleaseClimb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
- CLRBCellectar BiosciencesReleaseCellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Expo
- CLNNCleneReleaseClene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights→ BD updateSummary on the 8-K
- CLNNClene8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateThe Q3 10-Q reveals $9.9M cash, a ~$13M current debt wall, a fresh $7.2M NIH subaward, and management's first explicit disclosure that NDA acceptance could trigger $6.7M–$7.8M in warrant cash — all landing the same morning the stock jumped +8.8%.
- CLNNClene10-QQuarterly report→ BD updateSummary on the 8-K
- CLDXCelldex TherapeuticsReleaseCelldex to Present at Upcoming Investor Conferences
- CGEMCullinan TherapeuticsReleaseCullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting→ BD updateSummary on the 8-K
- CGEMCullinan Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateThe CLN-049 Phase 1 dataset — 87 patients, optimized dosing at 6 and 12 µg/kg — landed this morning and the stock dropped 20.7%, but the headline CRc compression vs. earlier data may be less damning than the tape suggests when you read the regimen change that drove it.
- BEAMBeam TherapeuticsReleaseBeam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
- BCRXBiocryst PharmaceuticalsReleaseBioCryst Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- BCRXBiocryst PharmaceuticalsReleaseBioCryst to Present at Upcoming Investor Conferences→ BD updateSummary on the 8-K
- BCRXBiocryst Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE→ BD updateBioCryst's Q3 print cleared the CareMed transition risk and accelerated the OMERS royalty-cap timeline, but investors should understand that headline ORLADEYO revenue was flattered by a mid-teens inventory build — the underlying business is tracking, not accelerating.
- BCRXBiocryst Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- AUTLAutolus TherapeuticsReleaseAUTOLUS THERAPEUTICS TO PRESENT CLINICAL DATA UPDATES AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2026
- ARVNArvinasReleaseArvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hemat
- ANTXAN2 TherapeuticsReleaseAN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London
- ANTXAN2 TherapeuticsReleaseAN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
- ANIXAnixa BiosciencesReleaseNOV 04, 2026 8:35 AM EST Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026↗ Robert Wenham, M.D., Chair of the G
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
- AGIOAgios PharmaceuticalsReleaseAgios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
- ADMAAdma BiologicsReleaseADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- ADMAAdma Biologics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateADMA's Q3 2026 print shows ASCENIV at $124.7M (+31% YoY, +21% sequentially), gross margin of 71%, and $105M of nine-month operating cash flow — clearing another gate on the path from Watch List toward conviction, while FDA pre-IND feedback on SG-001 adds a first pipeline milestone.
- ADMAAdma Biologics10-QQuarterly report→ BD updateSummary on the 8-K
- ADCTADC TherapeuticsReleaseADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program→ BD updateSummary on the 8-K
- ADCTADC Therapeutics8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateThe LOTIS-7 abstract data the entire thesis has been waiting for arrived after the close: 88.7% ORR and 75.3% CR across 97 evaluable r/r DLBCL patients, with responses deepening over time and median PFS not reached — and critically, a safety profile that looks far cleaner than LOTIS-5's fatal-infection disaster.
- ACTUActuate TherapeuticsReleaseACTUATE THERAPEUTICS TO PRESENT PROMISING PRECLINICAL DATA DEMONSTRATING ANTITUMOR AND IMMUNE ACTIVATION ACTIVITY OF ELRAGLUSIB ORAL TABLET IN ADVANCED MELANOMA MODELS AT ENA 2026
- ACRVAcrivon TherapeuticsReleaseAcrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- ACIUAC ImmuneReleaseAC Immune Third Quarter 2026 Financial and Corporate Update→ BD updateSummary on the 6-K
- ACIUAC Immune6-KForeign issuer report · EX-99.1→ BD updateAC Immune's Q3 update quietly extends cash runway to Q1 2028, pushes the hsCRP readout to H1 2027, and declares a Morphomer a-syn lead candidate — the balance sheet got better, the near-term catalyst calendar shifted, and the stock moved +9.6% on the news.
Tuesday, November 380
- ZURAZura BioEFFECTRegistration effective
- XFORX4 PharmaceuticalsReleaseX4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
- XENEXenon PharmaceuticalsReleaseXenon to Present at Upcoming Investor Conferences
- VNDAVanda PharmaceuticalsReleaseVanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences
- TNGXTango TherapeuticsReleaseTango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
- SYRESpyre TherapeuticsReleaseSpyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- SYRESpyre Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateSKYWAY's final two sub-studies (PsA and axSpA) missed their primary endpoints, closing the door on rheumatic diseases for SPY072 entirely — while SKYLINE Part B accelerates toward a Q3 2027 combination readout and the fortress balance sheet grows to $1.47B pro forma.
- SYRESpyre Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- STOKStoke TherapeuticsReleaseStoke Therapeutics to Present at Upcoming Investor Conferences in November
- STOKStoke Therapeutics10-QQuarterly report
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update→ BD updateSummary on the 8-K
- RYTMRhythm Pharmaceuticals8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 delivered another strong commercial beat ($92.1M, +29% QoQ, >700 PSFs) — but the market is selling the news because Rhythm simultaneously agreed to pay LG Chem $350M over four years to slash its bivamelagon royalty, financed by a new $750M term loan that adds meaningful leverage to a company still burning cash.
- RYTMRhythm Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- RLMDRelmada TherapeuticsReleaseRelmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026via aggregator
- RAREUltragenyx PharmaceuticalReleaseUltragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027→ BD updateSummary on the 8-K
- RAREUltragenyx Pharmaceutical8-KCurrent report: acquisition / disposition, results of operations, exit / restructuring costs · EX-99.1→ BD updateQ3 2026 earnings confirm the transformation is real: operating cash burn collapsed to $43M for the quarter, a second 20% workforce reduction is underway, UX701 is terminated, Angelman is officially wound down, and R&D spending is being cut in half — but 2027 GAAP profitability is reaffirmed and the balance sheet now has ~$750M+ of cash plus PRV proceeds incoming.
- PMNProMIS NeurosciencesReleaseProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
- ORKAOruka TherapeuticsReleaseOruka Therapeutics to Participate in Multiple Upcoming Conferences
- ORICOric PharmaceuticalsReleaseORIC® Pharmaceuticals to Participate in Upcoming Investor Conferencesvia aggregator
- OCSOculis HoldingReleaseOculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts→ BD updateSummary on the 6-K
- OCSOculis Holding6-KForeign issuer report · EX-99.1→ BD updatePREDICT-1 enrollment is complete at 176 patients with topline data due around year-end, while new ACUITY biomarker data, two senior neurology hires, and an expanded $125M ATM arrive as OCS trades at $7.63 — a 40% slide since the August update — compressing the EV to a level where the speculative math looks different.
- OCSOculis Holding424B5Prospectus supplement (offering)→ BD updateSummary on the 6-K
- NTLAIntellia TherapeuticsReleaseIntellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
- NRIXNurix TherapeuticsReleaseNurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272→ BD updateSummary on the 8-K
- NRIXNurix Therapeutics8-KCurrent report: other events→ BD updateSanofi has terminated the Phase 1 trial of SAR448272, its STAT6 degrader developed under the Nurix collaboration — permanently wiping ~$455M in future milestones from the "free carry" partnered pipeline I've been tracking since April. The reaction hasn't hit the tape yet, but the thesis needs a recalibration.
- NGNENeurogeneReleaseNeurogene to Participate in Upcoming Investor Conferences
- NAMSNewAmsterdam PharmaReleaseNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
- MLYSMineralys TherapeuticsReleaseMineralys Therapeutics to Participate in Upcoming Investor Conferences
- MISTMilestone PharmaceuticalsReleaseMilestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
- MESOMesoblast6-KForeign issuer report · EX-99.1
- MAZEMaze TherapeuticsReleaseMaze Therapeutics to Participate in Upcoming Investor Conferences
- LQDALiquidiaReleaseLiquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
- LENZLENZ Therapeutics10-QQuarterly report
- KURAKura OncologyReleaseKura Oncology to Report Third Quarter Financial Results on November 10
- KTTAPasithea TherapeuticsReleasePasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)→ BD updateThe FDA has cleared an IND for a randomized, placebo-controlled Phase 2 trial of PAS-004 in NF1-associated cutaneous neurofibromas — a 80,000-patient indication with zero approved systemic therapies, and the exact "label-expansion seed" I flagged in June.
- KAPAKairos PharmaReleaseKairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
- KAPAKairos Pharma8-KCurrent report: material agreement, other events · EX-99.1
- JBIOJade BiosciencesReleaseJade Biosciences to Participate in Upcoming Conferences
- IRDOpus GeneticsReleaseOpus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
- IDYAIDEAYA BiosciencesS-8Employee plan registration→ BD updateSummary on the 8-K
- IDYAIDEAYA BiosciencesReleaseIDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update→ BD updateSummary on the 8-K
- IDYAIDEAYA Biosciences8-KCurrent report: results of operations · EX-99.1→ BD updateOptimUM-010 is formally dead — IDEAYA just canceled the neoadjuvant Phase 3, banking $100-125M in savings to fund two IDE849 registrational trials (SCLC and NEC). The Q3 10-Q confirms the burn is accelerating and the SCLC bet is scaling fast.
- IDYAIDEAYA Biosciences10-QQuarterly report→ BD updateSummary on the 8-K
- HELPHelus PharmaReleaseHelus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
- HELPHelus Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- GERNGeronReleaseGeron Corporation to Participate in the Stifel 2026 Healthcare Conference
- FHTXFoghorn TherapeuticsReleaseFoghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
- EXELExelixisReleaseExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
- ERASErascaReleaseErasca to Present at Upcoming Conferences in November
- DTILPrecision BiosciencesSCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- DTILPrecision BiosciencesReleasePrecision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- DTILPrecision Biosciences8-KCurrent report: results of operations · EX-99.1→ BD updateQ3 numbers confirm the ATM is open again and cash is burning faster than the Q2 "discipline" signal suggested — but the bigger story is that new ELIMINATE-B data drops publicly on November 5 and hits the podium at AASLD on November 8, making this the most time-sensitive update since the August first-dosing post.
- DTILPrecision Biosciences10-QQuarterly report→ BD updateSummary on the 8-K
- DFTXDefinium TherapeuticsReleaseDefinium Therapeutics to Participate at Upcoming Investor Conferences
- CTNMContineum Therapeutics8-KCurrent report: results of operations · EX-99.1
- CTNMContineum Therapeutics10-QQuarterly report
- CRDLCardiol TherapeuticsSUPPLSUPPL→ BD updateSummary on the 6-K
- CRDLCardiol TherapeuticsReleaseCardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC→ BD updateSummary on the 6-K
- CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 NEWS RELEASE DATED NOVEMBER 3, 2026→ BD updateSummary on the 6-K
- CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateThe ATM dilution machine I warned about in September is now live: Cardiol activated a US$75M at-the-market offering through Jefferies, the exact scenario I flagged as a downside trigger — and the stock has already shed ~41% since the last update.
- CNTBConnect BiopharmaSCHEDULE 13G/A13G amendment
- CMPSCOMPASS PathwaysReleaseCompass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights→ BD updateSummary on the 8-K
- CMPSCOMPASS Pathways8-KCurrent report: results of operations · EX-99.1→ BD updateThe NDA is days away and $444M in cash funds the company into 2028 — so why is CMPS down 43% since September? The Q3 report answers the question, and the thesis is intact.
- CMPSCOMPASS Pathways10-QQuarterly report→ BD updateSummary on the 8-K
- CMMBChemomab Therapeutics6-KForeign issuer report
- CGENCompugenReleaseCompugen to Participate in November Investor Conferences
- CCCCC4 TherapeuticsReleaseC4 Therapeutics to Participate in Upcoming November Investor Conferences
- CAPRCapricor TherapeuticsReleaseCapricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10
- BEAMBeam TherapeuticsReleaseBeam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
- BEAMBeam Therapeutics8-KCurrent report: results of operations · EX-99.1
- BEAMBeam Therapeutics10-QQuarterly report
- BCTXBriaCell TherapeuticsReleaseBriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026via aggregator
- AXSMAxsome TherapeuticsReleaseAxsome Therapeutics to Participate in Upcoming Investor Conferences
- ARVNArvinasS-3Shelf registration→ BD updateSummary on the 8-K
- ARVNArvinasReleaseArvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- ARVNArvinas8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateQ3 earnings confirm ARV-6723 is now dosing patients, ARV-393 data lands at ASH in December, and $558.9M cash holds the fort — but the stock is at $7.09, the CMO seat is still empty, and a fresh $400M shelf registration raises dilution awareness heading into the catalyst window.
- ARVNArvinas10-QQuarterly report→ BD updateSummary on the 8-K
- ARDXArdelyxReleaseArdelyx Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD update
- ARDXArdelyxReleaseArdelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation→ BD update
- ARDXArdelyx8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD update
- ARDXArdelyx10-QQuarterly report→ BD update
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
- ALLOAllogene TherapeuticsReleaseAllogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
- ADCTADC TherapeuticsS-4Merger registration
- ADCTADC TherapeuticsReleaseADC Therapeutics to Present at November Investor Conferences
Monday, November 270
- XERSXeris BiopharmaReleaseXeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
- XERSXeris Biopharma8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- XENEXenon PharmaceuticalsReleaseXenon to Report Q3 2026 Financial Results on November 9, 2026
- VSTMVerastemReleaseVerastem Oncology to Participate in Upcoming November Investor Conferences
- VIRVir BiotechnologyReleaseVir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
- VERAVera TherapeuticsReleaseVera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- TVTXTravere TherapeuticsReleaseTravere Therapeutics Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- TVTXTravere Therapeutics8-KCurrent report: results of operations · EX-99.1→ BD updateFILSPARI hit $200M in a single quarter (+120% YoY) — another record print — while the IgAN patent finally issued and hit the Orange Book, the BIOSECURE injunction gave the API supplier a temporary reprieve, and ASN data reinforced the dual-blockade thesis one more time.
- TVTXTravere Therapeutics10-QQuarterly report→ BD updateSummary on the 8-K
- TLSATiziana Life SciencesReleaseTiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis→ BD updateSummary on the 6-K
- TLSATiziana Life Sciences6-K/AForeign issuer report (amended)→ BD updateSummary on the 6-K
- TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED NOVEMBER 2, 2026→ BD updateINFORM-MS hit its primary PET endpoint (p=0.0168) and safety primary — the first randomized, placebo-controlled evidence that a nasal anti-CD3 antibody reduces microglial activation in the brain. The science score just moved, but the stock is down 16% on the day, likely pricing in the near-certain dilutive raise that was always going to follow this result.
- TGTXTg TherapeuticsReleaseTG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
- SPRBSpruce BiosciencesReleaseSpruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- SNDXSyndax PharmaceuticalsRelease11.02.26 Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer - Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition -→ BD updateSummary on the 8-K
- SNDXSyndax PharmaceuticalsRelease11.02.26 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update – Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – – Revuforj ® (revumenib) net revenu→ BD updateSummary on the 8-K
- SNDXSyndax Pharmaceuticals8-KCurrent report: results of operations, officer / director change · EX-99.1→ BD updateRevuforj's Q3 print directly tests the NPM1m share-erosion tripwire I flagged in the writeup — and it holds: new patients accelerated 20% quarter-over-quarter with management claiming dominant share across all age groups, while the CFO transition adds a new strategic signal to decode.
- SNDXSyndax Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- SIONSionna TherapeuticsReleaseSionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
- RYTMRhythm PharmaceuticalsReleaseRhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
- RXRXRecursion PharmaceuticalsReleaseRecursion Appoints Fred Hassan as Chair of the Board→ BD updateSummary on the 8-K
- RXRXRecursion PharmaceuticalsReleaseNew Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps→ BD updateSummary on the 8-K
- RXRXRecursion PharmaceuticalsReleaseRecursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred→ BD updateSummary on the 8-K
- RXRXRecursion Pharmaceuticals8-KCurrent report: results of operations, officer / director change, Reg FD disclosure · EX-99.1→ BD updateThe CGA-IGC plenary I called a must-watch catalyst has landed — REC-4881's expanded TUPELO data strengthened across every GI compartment, and REC-1245 produced the first confirmed efficacy from a Recursion-designed molecule. The one watch-list trigger still outstanding: the FDA endpoint decision.
- RXRXRecursion Pharmaceuticals10-QQuarterly report→ BD updateSummary on the 8-K
- RNTXRein TherapeuticsReleaseRein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
- RLAYRelay TherapeuticsReleaseRelay Therapeutics to Participate in Three Upcoming Investor Conferences in November
- RCUSArcus BiosciencesReleaseArcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2...
- QUREuniQureReleaseuniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Diseasevia aggregator→ BD updateSummary on the 8-K
- QUREuniQure8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateThe FDA accepted the AMT-130 BLA under Priority Review with a May 1, 2027 PDUFA date — the exact binary I told readers to wait for in September — and the stock is inexplicably down 7.5% on the news, creating one of the more interesting re-entry setups this story has thrown off.
- OLMAOlema PharmaceuticalsReleaseOlema Oncology to Participate in Upcoming Investor Conferences
- OCSOculis HoldingReleaseOculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
- NVCTNuvectis PharmaReleaseNuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026via aggregator
- NRXPNRX Pharmaceuticals8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- NRSNNeuroSense TherapeuticsReleaseNeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data→ BD updateSummary on the 6-K
- NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED NOVEMBER 2, 2026→ BD updateThe Canadian NDS deadline slipped three months to March 2027 — extending the one near-term catalyst into the Nasdaq Panel's maximum window — while new NfL biomarker data from PARADIGM provides a genuine, if incremental, scientific positive. The stock is down 38.6% week-over-week and now trading well below the $5M immediate-delisting floor.
- MISTMilestone PharmaceuticalsReleaseNew Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
- LXEOLexeo TherapeuticsReleaseLexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in Novembercompany site may be offline after the acquisition
- LENZLENZ TherapeuticsSCHEDULE 13D/A13D amendment→ BD updateRA Capital — the "elite, science-literate" anchor I cited as a core conviction signal — sold its entire LENZ equity stake across three days this week, dropping from ~15.5% to 0.2% (warrants only). That changes the bull case in a way subscribers need to hear.
- KZIAKazia TherapeuticsReleaseKazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
- KZIAKazia TherapeuticsNT 20-FNT 20-F
- JANXJanux TherapeuticsReleaseJanux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
- IRONDisc MedicineReleaseWATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
- IONSIonis PharmaceuticalsReleaseIonis to hold third quarter 2026 financial results webcast
- INKTMiNK TherapeuticsReleaseMiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
- IMUXImmunicSCHEDULE 13G/A13G amendment
- IMUXImmunicReleaseImmunic to Participate in Investor Conferences in November
- IMNMImmunomeReleaseImmunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conferencevia aggregator
- HROWHarrowReleaseHarrow Launches HarrowRx Platform
- ETONEton PharmaceuticalsReleaseEton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
- ETONEton Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO INFANTILE SPASMS
- ELOXEloxx PharmaceuticalsReleaseEloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference
- EIKNEikon TherapeuticsReleaseEikon Therapeutics to Participate in Multiple Investor Conferences in November
- DBVTDBV TechnologiesReleaseDBV Technologies to Participate in Upcoming November Investor Conferences
- CTMXCytomX TherapeuticsReleaseCytomX Therapeutics to Present at Upcoming November Investor Conferences
- CMPXCompass TherapeuticsReleaseCompass Therapeutics to Participate in Upcoming November Investor Events
- CMPSCOMPASS PathwaysReleaseNew Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers
- CMMBChemomab TherapeuticsReleaseChemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effectivecompany site may be offline after the acquisition
- CLYMClimb BioReleaseClimb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
- CLRBCellectar BiosciencesReleaseCellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 LEARN MORE
- CGTXCognition TherapeuticsReleaseCognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
- CBIOCrescent BiopharmaReleaseCrescent Biopharma to Present at November Investor Conferences
- BCAXBicara TherapeuticsReleaseBicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET
- AXSMAxsome TherapeuticsReleaseAxsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD update
- AXSMAxsome Therapeutics8-KCurrent report: results of operations, other events · EX-99.1→ BD update
- AXSMAxsome Therapeutics10-QQuarterly report→ BD update
- APVOAptevo Therapeutics8-KCurrent report: other events
- ANTXAN2 TherapeuticsReleaseAN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
- AMLXAmylyx PharmaceuticalsReleaseAmylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
- ADCTADC TherapeuticsReleaseADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
- ACTUActuate TherapeuticsReleaseACTUATE THERAPEUTICS RECEIVES U.S. NOTICE OF ALLOWANCE FOR PATENT COVERING ELRAGLUSIB ORAL TABLETS
- ABVXAbivaxReleaseAbivax to Participate in Upcoming Fall Investor Conferences
Sunday, November 11
- MESOMesoblastReleaseMesoblast Board Changesvia aggregator→ BD updateTwo directors retire ahead of Mesoblast's November 10 AGM — including Philip Krause, whose son's firm was hired to publish the LVAD BLA. The board changes partially address governance concerns I flagged, but the key question — whether George's nominee Voigtman still stands — remains unanswered.